Development of a DNA vaccine against SARS-CoV: negative regulation of the IFN-α signaling by the influenza matrix protein (M1) by Oberle, Bettina Thea
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2006
Development of a DNA vaccine against SARS-CoV: negative regulation of
the IFN-￿ signaling by the influenza matrix protein (M1)
Oberle, Bettina Thea
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-163589
Dissertation
Published Version
Originally published at:
Oberle, Bettina Thea. Development of a DNA vaccine against SARS-CoV: negative regulation of the
IFN-￿ signaling by the influenza matrix protein (M1). 2006, University of Zurich, Faculty of Science.
© Bettina T. Oberle 
DEVELOPMENT OF A DNA VACCINE AGAINST 
SARS-COV 
 
 
NEGATIVE REGULATION OF THE IFN-α SIGNALING 
BY THE INFLUENZA MATRIX PROTEIN (M1) 
 
 
 
Dissertation 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
Bettina Thea Oberle 
von Full-Reuenthal, AG 
 
 
Promotionskomitee 
Prof. Dr. Karin Mölling (Vorsitz) 
Prof. Dr. Urs Greber 
PD Dr. Jovan Pavlovic (Leitung der Dissertation) 
 
 
Zürich, 2006 
 i
Table of Contents 
ABBREVIATIONS                       i 
SUMMARY I                       1 
SUMMARY II                     3 
 
PART I 
1 INTRODUCTION .................................................................................................................................5 
1.1 SEVERE ACUTE RESPIRATORY SYNDROME-CORONAVIRUS (SARS-COV) ...............................5 
1.1.1 Viral Multiplication Cycle .................................................................................................7 
1.2 S PROTEIN..................................................................................................................................10 
1.2.1 Characterization of Coronavirus S Protein .................................................................10 
1.2.2 Localization of the S-Protein.........................................................................................11 
1.3 VACCINES ...................................................................................................................................12 
1.3.1 Conventional Vaccines ..................................................................................................12 
1.3.2 DNA Vaccines.................................................................................................................13 
1.3.3 SARS-CoV as Model: Antiviral Agents and Vaccines...............................................15 
1.3.3.1 Naked DNA ......................................................................................................................... 16 
1.3.3.2 Viral Vectors........................................................................................................................ 16 
1.3.4 Immune Responses Induced by DNA Vaccine..........................................................17 
1.3.5 Animal Model ..................................................................................................................18 
1.4 DIG’S AND GPI-ANCHORED PROTEINS.....................................................................................19 
1.4.1 Glycosyl Phosphatidyl Inositol (GPI)-Anchored Proteins .........................................20 
1.5 AIMS OF THIS PROJECT ..............................................................................................................21 
2 MATERIALS AND METHODS........................................................................................................23 
2.1 PLASMID CONSTRUCTION ..........................................................................................................23 
2.2 CELL CULTURE ...........................................................................................................................24 
2.3 TRANSFECTION...........................................................................................................................24 
2.3.1 Calcium-Phosphate Transfection.................................................................................24 
2.3.2 Lipofectamine Transfection...........................................................................................24 
2.4 PROTEIN ASSAY’S ......................................................................................................................25 
2.4.1 Plasma Membrane Extraction ......................................................................................25 
2.4.2 Lipid Raft Extraction.......................................................................................................25 
2.4.3 Immunofluorescence .....................................................................................................26 
2.5 ANTIBODIES AND WESTERN BLOTTING......................................................................................27 
2.6 MICE ...........................................................................................................................................27 
2.7 EVALUATION OF MICE SERA ......................................................................................................27 
2.7.1 SARS-CoV Indirect Immunofluorescence test ...........................................................27 
2.7.2 ELISA with recombinant soluble S protein of SARS-CoV ........................................28 
3 RESULTS...........................................................................................................................................29 
3.1 CHARACTERIZATION OF HA-TAGGED AND GPI-ANCHORED S-PROTEINS COMPARED TO WILD 
TYPE SF PROTEIN ....................................................................................................................................29 
3.2 ENHANCED EXPRESSION OF HA-TAGGED SF...........................................................................31 
3.2.1 Western Blot Analysis....................................................................................................31 
3.2.2 Bioinformatic Analysis ...................................................................................................32 
3.3 ISOLATION OF GPI-ANCHORED S-PROTEINS IN DIG’S..............................................................33 
3.3.1 Western Blot Analysis....................................................................................................33 
3.3.2 Bioinformatic Analysis ...................................................................................................34 
3.4 VACCINATION WITH HASF, SFG AND HASFG SIGNIFICANTLY IMPROVED THE IMMUNE 
RESPONSE ................................................................................................................................................35 
3.4.1 ELISA ...............................................................................................................................36 
3.4.2 Indirect Immunofluorescence Assay ...........................................................................37 
 ii 
4 DISCUSSION.....................................................................................................................................39 
5 OUTLOOK .........................................................................................................................................46 
 
PART II 
6 INTRODUCTION ...............................................................................................................................47 
6.1 THE INTERFERON (IFN) SYSTEM ...............................................................................................47 
6.1.1 Gene Induction of Type I IFN .......................................................................................48 
6.1.2 IFN-α/β Induced Signal Transduction .........................................................................50 
6.1.3 Interferon Stimulated Genes (ISGs) with Antiviral Activity .......................................52 
6.1.3.1 Mx Proteins ......................................................................................................................... 52 
6.1.3.2 ds-RNA activated protein kinase R (PKR) ...................................................................... 53 
6.1.3.3 2’5’-Oligoadenylate Synthetase (OAS) ........................................................................... 53 
6.1.4 Viral Evasion ...................................................................................................................53 
6.1.4.1 Viral Host Cell Shut-Off ..................................................................................................... 54 
6.1.4.2 Viral Interference with the IFN Induction Pathway ........................................................ 54 
6.1.4.3 Inhibition of IFN-α/β Signaling .......................................................................................... 55 
6.1.4.4 Inhibition of IFN Effector Proteins .................................................................................... 56 
6.2 INFLUENZA A VIRUS ....................................................................................................................57 
6.2.1 Influenza Virus Life Cylce..............................................................................................58 
6.2.2 Influenza Matrix Protein M1 ..........................................................................................60 
6.3 AIM OF THIS PROJECT................................................................................................................61 
7 MATERIALS AND METHODS........................................................................................................62 
7.1 CELL CULTURE AND TRANSFECTION .........................................................................................62 
7.2 VIRUS INFECTION WITH INFLUENZA A/WSN/33 ........................................................................62 
7.3 DUAL-LUCIFERASE® REPORTER ASSAY ...................................................................................62 
7.4 PROTEIN EXTRACTION ...............................................................................................................63 
7.5 ANTIBODIES AND WESTERN BLOTTING......................................................................................64 
7.6 CO-IMMUNOPRECIPITATION .......................................................................................................64 
7.7 STATISTICS .................................................................................................................................65 
8 RESULTS...........................................................................................................................................66 
8.1 INHIBITORY EFFECT OF INFLUENZA A ON THE IFN-α/β SIGNALING ..........................................66 
8.1.1 Influenza Infection Decreases the Responsiveness of ISRE in a Reporter Assay
 66 
8.2 INHIBITORY EFFECT OF INFLUENZA M1 ON THE IFN-α/β SIGNALING ........................................68 
8.2.1 Overexpression of M1 Decreases the Responsiveness of ISRE in a Reporter 
Assay 68 
8.2.2 Overexpression of M1 Decreases the Responsiveness of ISRE in a Reporter 
Assay Similar to the SV5 V-Protein ................................................................................................69 
8.3 INFLUENZA A INHIBITS MXA .......................................................................................................71 
8.3.1 Influenza Infection or Overexpression of M1 Inhibit the Expression of MxA .........72 
8.4 INHIBITION OF STAT1 PHOSPHORYLATION BY INFLUENZA A....................................................73 
8.4.1 Influenza A did not Affect the Stability of IFN-α/β Signaling Proteins at Early 
Stages After Infection .......................................................................................................................73 
8.4.2 Influenza A Leads to the Inhibition of P-STAT1, but Does not Affect the Protein 
Level of STAT1 ..................................................................................................................................74 
8.4.3 Overexpression of M1 Leads to the Inhibition of Nuclear Translocation of STAT1
 75 
8.5 INHIBITION OF TYK2 PHOSPHORYLATION BY INFLUENZA A .......................................................76 
8.6 INHIBITION OF STAT2 AND JAK1 PHOSPHORYLATION BY INFLUENZA A...................................77 
8.7 PHOSPHORYLATION OF IFN-α/β SIGNALING PROTEINS UPON M1 TRANSFECTION ................78 
8.8 JAK1, TYK2, STAT2 AND RACK1 AS INTERACTION PARTNERS OF M1 ..................................80 
 iii
9 DISCUSSION.....................................................................................................................................83 
10 OUTLOOK.....................................................................................................................................90 
11 REFERENCES .............................................................................................................................91 
12 ACKNOWLEDGMENTS ...........................................................................................................106 
 
 
 i 
ABBREVIATIONS 
A549 human lung carcinoma cell  
line 
ACE2 angiotensin converting enzyme 2 
BCV bovine coronavirus 
CoV Coronavirus 
CMV cytomegalovirus 
CpG non-methylated dinucleotide, C-Gs, linked 
by a phosphodiester bond 
cRNA cellular RNA 
DIG detergent-insoluble glycosphingolipids 
E Envelope protein; SARS-CoV 
ELISA enzyme linked immunoabsorbent assay 
ER endoplasmic reticulum 
FCS fetal calf serum 
GPI glucosyl phosphatidyl inositol 
HASF Spike with HA-leader sequence and Flag-
epitope 
HASFG Spike with HA-leader sequence, Flag-
epitope and GPI-anchor sequence 
HCV human coronavirus 
HE hemagglutinin esterase 
HEK 293 human embryonal kidney cells 
HR heptad repeat 
HSV herpes simplex virus 
IBV avian infectious bronchitis virus 
i.d. intradermally 
i.m. intramuscular 
i.n. intranasally 
IFN  interferon 
IFNAR interferon α receptor 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IRF Interferon regulatory factor 
ISRE interferon-stimulated response element 
ISG interferon-stimulated gene 
ISGF interferon-stimulated gene factor 
Jak janus kinase 
M Matrix protein of SARS-CoV 
M1 Matrix protein of Influenza A 
M2 Ion channel (H+) of Influenza A 
MDCK Madin-Darby canine kidney 
MHV mouse hepatitis virus 
MLV mouse leukemia virus 
mRNA messenger RNA 
MxA myxovirus resistance protein A 
N Nuclear protein of SARS-CoV 
NA Neuraminidase 
NC ribonucleoprotein core 
NP Nucleoprotein 
NS1 non-structural protein 1 
NS2 non-structural protein 2 
PA protein acidic 
PB1 protein basic 1 
PB2 protein basic 2 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PKR protein kinase R 
PKC protein kinase C 
RACK1 receptor of activated kinase C 1 
RBD receptor binding domain 
RNP ribonucleoprotein 
S Spike protein; SARS-CoV 
SF Spike with Flag-epitope 
SFG Spike with Flag-epitope and GPI- 
 anchor sequence 
SARS severe acute respiratory syndrome 
STAT signal transducer and activator of 
transcription 
SV5 simian virus 5 
SV40 simian virus 40 
TGEV transmissible gastroenteritis virus 
 of swine 
Tyk tyrosine kinase 
Vero E6 African green monkey kidney cells 
WHO World Health Organisation 
WSN  
vRNA viral RNA 
 
 1
Summary: Part I 
Classical vaccine strategies include the development of attenuated organisms, 
whole killed organisms, and protein subunits. These traditional vaccination 
methods have remained ineffective to several important emerging viruses like 
HIV, herpes, dengue fever, hepatitis C and influenza. Consequently, new 
technologies are required. Plasmid DNA expressing an antigen of interest is a 
new approach for immunization. Injection of DNA vaccines results in antigen 
expression in transfected host cells, and priming of both humoral and cellular 
immune responses. DNA vaccines induce potent immune responses in various 
animal models, but only modest immune responses in clinical trials. Different 
strategies have been used to increase the potency of DNA vaccines. Plasmids 
have been altered, by sequence optimization of the antigen, or insertion of 
bacterial CpG motifs to improve the immune response. Furthermore, DNA 
vaccines are co-administered with chemokines, cytokines and other molecules to 
enhance their efficiency, or applied in prime-boost regimens, together with a viral 
vector or a recombinant protein. 
The aim of this study was to improve the immunogenicity of plasmid DNA by 
genetic modifications of the antigen of interest. As a target antigen we chose the 
severe acute respiratory syndrome coronavirus (SARS-CoV) S-protein. The 
SARS-CoV epidemic in 2003 identified a new etiologic agent providing a new 
challenge to find a potent vaccination. The S-protein is the major viral 
glycoprotein protruding from the viral shell and identified as the main antigen of 
the virus. The S-protein is known to be a weak antigen (Yang et al., 2004) and 
optimization of the antigen presentation at the cell surface was suggested to 
improve antigenicity. 
The genetic modifications include two different strategies: (1) Exchange of the 
leader sequence of the S-protein (SF; S-protein with a Flag-epitope) with the 
influenza A haemagglutinin (HA) leader sequence (HASF), which should result in 
enhanced expression of the antigen and increased trafficking to the cell surface 
(Xiao et al., 2003). (2) Replacement of the transmembrane (TM) and the 
cytoplasmic (CP) region of the S-protein by the sequence for glycosyl-
 2 
phosphatidyl-inositol (GPI)-anchor attachment for SF and HASF, resulting in SFG 
and HASFG, respectively. GPI-anchors redirect proteins to lipid rafts, special 
microdomains of the plasma membrane (Brown & Waneck, 1992, Brown, 1992, 
Laude & Prior, 2004, Simons & Ikonen, 1997), which should increase and 
optimize the presentation on the cell surface. 
The results of this study showed enhanced expression for HASF compared to the 
S-protein (SF). Furthermore, SFG and HASFG were co-localized with detergent-
insoluble membranes (lipid rafts). HASFG, the S-protein displaying both genetic 
modifications showed increased expression as well as co-localization with lipid 
rafts. The immune response in mice was measured for the different S-protein 
constructs. Mice transfected with a plasmid coding for HASF or SFG showed a 
two-fold increase in their antibody titer compared to SF. Transfection with p-
HASFG enhanced the antibody titer three-fold compared to SF. The HA leader 
sequence as well as the GPI-anchor sequence were identified to improve the 
presentation at the cell surface and therefore to enhance the immune response in 
mice. In conclusion, this study revealed three genetically modified immunogens 
against the SARS-CoV inducing an improved antibody response in mice. The 
genetic modifications may provide a technology platform for enhancement of the 
immune response. 
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Summary: Part II 
Complex organisms have evolved sophisticated mechanisms to prevent and 
control infection by various pathogens or viruses. Among these mechanisms the 
interferon (IFN) system, which is part of the innate immune system, represents 
the first step of defense against viral infection in vertebrates. Secretion of IFNs 
prepares uninfected cells for combating oncoming virus. Products of IFN-
stimulating genes (ISGs) mediate an antiviral action (reviewed in (Sarkar & Sen, 
2004)). Once an antiviral state has been established in an infected cell, protein 
synthesis is inhibited and apoptosis may be initiated. The invading virus will be 
impaired in infection and replication, which provides time for an adaptive immune 
response (Stark et al., 1998). Therefore, viruses must overcome the antiviral 
response provided by the cell in order to establish infection (Alcami, 2003, 
Samuel, 2001). They found intriguing ways in multiple pathways to evade the IFN 
system of the host organism. 
The influenza A virus is counteracting the IFN system by inhibiting the type I IFN 
production through the non-structural viral protein 1 (NS1). Paradoxically delNS1, 
the NS1 deletion mutant of influenza virus, could still propagate in the host cell 
(Garcia-Sastre et al., 1998b). This observation suggested a second mechanism 
by which the virus was able to circumvent the cellular defense mechanisms. 
However, no conclusive results have been obtained. 
This study demonstrates an antagonistic activity of the M1-protein of influenza A 
in the IFN-α signaling pathway. An IFN-stimulated response element (ISRE)-
promoter-driven reporter system was used to detect the negative regulation of 
the IFN signaling cascade by the M1-protein. This effect was independently 
confirmed by direct measurement of MxA transcript levels in influenza A infected 
cells. These data identified the IFN-α signaling cascade as target of the virus. 
The M1-protein did not exert an effect on IFN transcription, suggesting that in 
contrast to the influenza NS1 protein, it interfered with the action rather than the 
production of IFN-α. M1 was shown to inhibit the phosphorylation of several IFN-
α signaling proteins and to interact with Janus kinase 1 (Jak1), tyrosine kinase 2 
(Tyk2) and receptor activated kinase C 1 (RACK1). In conclusion, this study 
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elicited an alternative mechanism of influenza A to counteract the innate immune 
response. 
 5
PART I 
 
 
1 INTRODUCTION 
1.1 SEVERE ACUTE RESPIRATORY SYNDROME-
CORONAVIRUS (SARS-COV) 
In late 2002, cases of a life-threatening respiratory disease with no identifiable 
cause were reported from Guangdong Province, China. By the time of March 
2003, there has been a worldwide outbreak of the severe acute respiratory 
syndrome (SARS), transmitted through a novel coronavirus strain (SARS-CoV). 
SARS is a serious respiratory illness that leads to significant morbidity and 
mortality in elderly populations (Table 1). Aggressive quarantine measures 
successfully terminated the disease. The SARS epidemic was officially controlled 
by July 2003 (Ashraf, 2003, Fleck, 2003). Currently, there are no SARS cases 
recorded and most likely the virus does not circulate anymore. 
 
 
Table 1: General information and statistics obtained upon the SARS-CoV outbreak. 
 
The natural reservoir of SARS-CoV is currently unknown. SARS-CoV is likely 
transmitted from animal hosts to humans. The virus rapidly adapted to the new 
 6 
host and not only became transmissible between humans but also more 
pathogenic. There is a possibility that SARS-CoV gets transmitted again from its 
natural host to humans. Therefore it is important to develop a vaccine, providing 
protective immunity. 
SARS-CoV belongs to the family of Coronaviridae (Table 2). Coronaviruses are 
found in a wide range of animal species. Animal and human coronaviruses have 
been classified into three different serological groups based on their antigenicity. 
SARS-CoV is not closely related to any subgroup of known CoVs, although it is 
suggested to resemble most the group II CoVs (Snijder et al., 2003). 
 
 
Table 2: The order of the nidovirales and their subfamily. 
 
Coronaviruses are enveloped, round shaped viruses of approximately 80-120 nm 
in diameter, with a positive-stranded large genomic RNA. The genome of SARS-
CoV is 29’727 nucleotides in length. The full length genome sequence of SARS-
CoV has been elucidated within few weeks after the identification of this novel 
pathogen (Rota et al., 2003). Coronavirions contain several structural proteins: 
the Spike glycoprotein (S), which forms the 20-nm glycosylated peplomers 
characteristic for coronaviruses, protruding from the virion envelope. The 
membrane protein (M) is spanning the membrane three times and the envelope 
protein (E) are two more glycoprotein,. The nucleocapsid protein (N), associated 
with the genomic RNA, and the hemagglutinin esterase glycoprotein (HE), which 
is protruding the shell and exists in some of the group II Coronaviruses (see 
Figure 1). SARS-CoV does not include the structural protein HE. 
The genomic organization of the SARS-CoV RNA is typical for coronaviruses, 
having the characteristic gene order 5‘-replicase (rep), spike (S), envelope (E), 
membrane (M), and nucleocapsid (N)-3‘ and short untranslated regions at both 
termini. In addition to the conserved genes, the SARS-CoV genome contains 
NidoviralesOrder
Family Coronaviridae Arteriviridae
Coronaviruses
Toroviruses
Subfamily Equine arteritisvirus
Lactatehydrogen-induced virus (mouse)
Simian haemorrhagic fever virusi
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eight novel ORFs at the 3’ end (Snijder et al., 2003). To date, the functions of 
these genes remain unknown, although their absence from other genomes 
suggests unique functions that might be advantageous to SARS-CoV replication, 
assembly or virulence (Ziebuhr, 2004). 
 
 
Figure 1: Model of a coronavirus particle. The virus particle consists of 
an internal helical RNA-protein nucleocapsid surrounded by an 
envelope. N is complexed with genomic RNA to form the nucleocapsid. 
S forms the large glycosylated peplomers. M is hydrophobic. E is a 
minor component of the membrane. The hemagglutinin-esterase (HE), 
another glycoprotein present only in some coronaviruses, forms smaller 
spikes on the virion (adapted from Weiss and Navas-Martin, 2005). 
 
1.1.1 VIRAL MULTIPLICATION CYCLE 
The first step in viral infection is the binding of viral proteins to a cellular receptor. 
Coronaviruses bind to specific cellular receptors via the S-protein (Fig. 2). It has 
been shown that a cellular metallopeptidase, angiotensin-converting enzyme 2 
(ACE2), binds a 193 AA fragment of the SARS-CoV S-protein (Li et al., 2004). 
SARS-CoV has the potential to enter cells via two different pathways, depending 
on the presence of proteases in the environment. One possibility is the binding of 
SARS-CoV S-protein to its cellular receptor ACE2, which promotes internalization 
into endosomes (Simmons et al., 2004). Proton influx into the endosome can 
trigger the membrane fusion by acidification. If proteases like trypsin or 
thermolysin are present in the environment, SARS-CoV is adsorbed onto the cell 
surface, proteases cleave the S-protein, which leads to a conformational change 
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of the S-protein and mediates fusion between the viral and cellular membranes. 
This results in the release of the nucleocapsid into the cell. Protease-mediated 
entry resulted in over a 100-fold more efficient infection than entry through 
endosomes (Matsuyama et al., 2005). 
 
The genomic RNA of coronaviruses is capped and polyadenylated and serves as 
an mRNA for synthesis of the RNA-dependent RNA polymerase (Fig. 2). Upon 
entry into the cell, the 5’ end of the genomic RNA, ORFs 1a and 1b, are 
translated into pp1a and pp1ab; pp1ab is translated via a ribosomal frameshift 
mechanism (Bredenbeek et al., 1990). Proteolytic processing of pp1a and pp1ab 
leads to the production of the mature polymerases, that form the replicase 
complex. Using the genomic RNA as template, the polymerase generates a full 
length, minus-strand that contains a 5’ poly-U sequence. New plus strand 
genomic RNAs and a 3’co-terminal nested set of subgenomic mRNAs are 
generated from the minus-strand template. A leader RNA (60 - 90 bases) is 
found in the genome only once at the 5’ end, and is also found at the 5’end of 
each mRNA.  
Subgenomic mRNAs of Coronaviruses consist of a ‘leader’ and a ‘body’ fragment 
that are non-contiguous in the genome sequence: they are transcribed from 
sequences in the 3’end and the 5’-terminal part of the genomic (-) strand RNA, 
respectively. The connection between the two segments of the subgenomic 
mRNA is formed by a conserved junction site sequence that is found both at the 
3’end of the common leader sequence and at the 5’end of the mRNA body. 
Proteins are translated from the first AUG after the leader sequence at the 5’end 
of each mRNA. 
The membrane protein (M) plays a key role in assembly of coronaviruses. It has 
the ability to form a complex with the S and HE glycoproteins (Nguyen & Hogue, 
1997), or the S-protein alone for the viruses that do not contain the HE protein 
(Opstelten et al., 1995b). The S-protein is prevented from being transported to 
the plasma membrane (PM), but instead the M protein retains it intracellularly. 
Thus, specific M-S interactions determine the intracellular transport of the S 
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protein and direct its packaging into virus particles. The nuclear protein (N) binds 
the genomic RNA via the leader sequence. It recognizes a stretch of RNA that 
serves as a packaging signal and leads to the formation of the helical 
ribonucleoprotein (RNP) complex during assembly (Lai & Cavanagh, 1997). The 
RNP presumably needs to interact with the envelope proteins to ensure its 
uptake into virions. 
 
 
Figure 2: Model of Coronavirus replication. (1) virus binds to cellular receptor and enters 
host cell. (2) ORF1a and ORF 1ab are tranlated from the genomic RNA to produce the viral 
RNA polymerase. (3) Genomic RNA is transcribed into (-) stranded RNA and subsequently 
into genomic RNA for progeny virus particles and subgenomic RNA for the synthesis of 
structural proteins. (4) Structural proteins are produced in the rough ER (RER). (5) Structural 
proteins undergo interaction with each other in the intermediate compartment (ERGIC). (6) 
Structural proteins are processed in the golgi compartment and viral particles assembled in 
(7) endosomes, which travel to the cell surface and release the progeny virus (8). 
 
Virus budding occurs intracellularly at membranes of the intermediate 
compartment, between the endoplasmic reticulum (ER) and the Golgi complex 
(ERGIC). Virus particles bud into the lumen of these intracellular compartments. 
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As shown in Figure 3, newly assembled virions are transported by vesicular 
transport to the cell surface, where they are released via exocytosis (Garoff et al., 
1998). 
 
Figure 3: Visualization of coronavirus budding and 
release through electron microscopy (picture from 
www.un.com). Black arrow indicates virus particles 
in vesicles; red arrow indicates virus particles at the 
cell surface. 
1.2 S PROTEIN 
1.2.1 CHARACTERIZATION OF CORONAVIRUS S PROTEIN 
The S-protein is a type I membrane protein that is synthesized as a precursor in 
the rough ER of the host cell and co-translationally N-glycosylated. The SARS-
CoV S-protein is subdivided into an N-terminal part (S1) and a C-terminal part 
(S2). S1 is responsible for binding to cellular receptors and thus determines the 
host range and tissue tropism. Whereas S2 contains an internal fusion peptide 
and is responsible for virus and host cell membrane fusion for cell entry 
(Gallagher & Buchmeier, 2001). The mature protein is assembled in homo-
oligomers. Homotrimers of S are extremely stable, such that S oligomers are 
partially resistant to SDS denaturation and reduction (Delmas & Laude, 1990). 
 
The SARS-CoV S-protein consists of 1255 amino acids (aa), where aa 1-1195 
represent the extracellular part, aa 1196-1218 the transmembrane and 1219-
1255 the intracellular part (Fig. 10). A leucine zipper motif terminates 10 amino 
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acid residues close to the transmembrane domain. The leucine zipper motif of 
the S-protein contains 5 heptad repeats. By analogy to the role of the leucine 
zipper domain in several transcription factors, it has been suggested that the 
motif may be responsible for the oligomerization of the S-protein. 
The S-protein contains 23 putative N-linked glycosylation sites, among which 12 
have already been verified (Krokhin et al., 2003, Ying et al., 2004). S-trimers are 
formed in the ER of the host cell and move towards the Golgi to acquire complex 
N-glycans (Nal et al., 2005, Niemann et al., 1982). 
Mature S-proteins of most coronaviruses are cleaved by host cell proteases 
located in the Golgi apparatus to yield S1 and S2 (Frana et al., 1985). The 
SARS-CoV S-protein lacks this basic amino acid cleavage site found in group II 
and group III coronaviruses (Rota et al., 2003), and shortly after the discovery of 
SARS-CoV, the S-protein was predicted not to be proteolytically cleaved 
(Supekar et al., 2004). Nevertheless, as demonstrated lately by Simmons and co-
workers, the S-protein seems to be proteolytically cleaved by cathepsin L 
(Simmons et al., 2005). Thus, it is reasonable to assume that the S-protein has a 
different cleavage site. 
1.2.2 LOCALIZATION OF THE S-PROTEIN 
When S-proteins from different coronaviruses are exogenously expressed, a 
large portion remains intracellular (Vennema et al., 1993) The infectious 
bronchitis virus glycoprotein was reported to be intracellularly retained because 
of a dilysine motif, resulting in retention in the ER (Lontok et al., 2004), whereas 
the porcine coronavirus (transmissible gastroenteritis virus; TGEV) exhibits a 
novel sorting signal for intracellular localization (Schwegmann-Wessels et al., 
2004). Co-expression of the glycoproteins M and E affects the intracellular 
transport of the S-protein of MHV: instead of being transported to the cell surface, 
the S-protein is retained intracellularly by its association with the M-protein 
(Opstelten et al., 1995a). 
Retention and transport of the SARS-CoV S-protein is still a matter of 
controversial discussion. The transport of SARS-CoV S-protein to the cell surface 
 12 
was currently shown and compared to the control TGEV S-protein in an 
immunofluorescence study. The TGEV S-protein contains a tetrapeptide (YEPI) 
for intracellular retention. A SARS-CoV S-protein double mutant was 
predominantly retained intracellularly (Schwegmann-Wessels et al., 2004). 
Another research group (Lontok et al., 2004) discovered a dibasic signal 
(KXHXX) at the C-terminal 11 amino acids of the TGEV S-protein as well as the 
SARS-CoV S-protein. This signal is similar to the dilysine signal in the IBV S-
protein (KKXX). Mutagenesis of the dibasic motif (KXHXX) resulted in loss of 
intracellular localization. The KXHXX signal is likely to contribute to the 
localization of the S-protein in the ERGIC. 
1.3 VACCINES 
1.3.1 CONVENTIONAL VACCINES 
The English physician Edward Jenner first employed the principle of vaccination 
in the 18
th
 century. He used cowpox virus to combat smallpox infections (Jenner 
E., Reprinted by Cassell, 1986, London). Since the introduction of vaccination in 
the 1950s and 1960s there have been a steady stream of new vaccines 
becoming available. Numerous viral diseases are successfully treated by 
vaccination, as depicted in Table 3. 
The production of conventional vaccines utilizes two different strategies: (1) 
attenuation of virulent organisms, or (2) killing of virulent organisms. Live 
attenuated vaccines are developed by growing viruses for generations under 
sub-optimal conditions (e.g. in tissue culture at 25°C). These viruses can still 
replicate in humans, but do not cause a disease. The oral polio vaccine has, as 
well as vaccines for mumps, measles and rubella have been developed by this 
method. Dead vaccines are produced from whole organisms that have been 
killed (e.g. by formaldehyde treatment). Inactivated pathogens do not replicate 
and cause no disease in the host. Dead vaccines in use today include those 
against polio and influenza virus. 
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Table 3: Human viral vaccines, currently available commercially.  
1.3.2 DNA VACCINES 
DNA vaccines are plasmids encoding viral antigens, which are expressed in the 
immunized host. The most commonly used plasmids utilize a minimal backbone 
containing a selectable marker, an origin of replication active in Escherichia coli 
(E.coli), a strong viral promoter active in eukaryotic cells, such as the immediate 
early CMVintA promoter, and a transcriptional chain terminator or 
polyadenylation signal sequence. The potential of a DNA vaccine plasmid to 
induce an effective immune response is directly related to the level of expression 
of the encoded protein in eukaryotic cells (Montgomery et al., 1994). DNA 
plasmids have been widely used to develop vaccines against various pathogens 
as well as for cancer, autoimmune disease and allergy. 
DNA vaccination involves the introduction of nucleic acid into tissues for 
expression in host cells. Unlike gene therapy, genetic integration is not intended. 
Indeed, the construction of a DNA vaccine is designed to permit localized, short-
term expression of the target antigen (Donnelly et al., 2003). However, DNA 
vaccines can be randomly integrated into host cell DNA by recombination. The 
probability of such an event lies between 10-6 and 10-7 per transfected cell. Since 
myocytes, the main targets of the injected DNA (Liu, 2003), are non-dividing 
cells, the frequency of integration of foreign DNA into these cells should be even 
Disease Vaccine type
Adenovirus Live attenuated
Chicken pox (VZV) Live attenuated
Hepatitis A Inactivated
Hepatitis B Subunit (genetically engineered)
Influenza Subunit
Japanese encephalitis Inactivated
Measles Live attenuated
Mumps Live attenuated
Poliomyelitis Live attenuated ( Sabin); Inactivated ( Salk)
Rabies Live attenuated
Rotavirus Live attenuated
Rubella Live attenuated
Smallpox Live attenuated
Tick-borne encephalitis Inactivated
Yellow fever Live attenuated
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lower. Avoiding the insertion of sequence repeats can minimize the risk of 
recombination events. These repeats could create transposon-like elements, 
enabling the integration. The integration of plasmid DNA however, may cause no 
effect on the expression of endogenous genes (Rajcani et al., 2005). 
If the corresponding DNA vector is delivered into muscle tissue or to skin 
epidermis, the expressed protein elicits a specific cytotoxic T cell (CTL) response 
as well as antibody production (Rajcani et al., 2005). 
DNA vaccines have several advantages compared to recombinant protein 
subunit vaccines produced in bacteria or yeast. The plasmid-encoded protein is 
produced endogenously and therefore folded and glycosylated identical as 
through infection. Thus conformational epitopes might be presented correctly to 
the host immune system. Furthermore, it is of great importance to design 
products that are easy to manufacture on an industrial scale and in non-
industrialized countries, which is the case for naked DNA vaccines (Moelling, 
1998). 
It has been more than a decade ago, since the first publications reported that 
immune responses could be induced by the injection of bacterial plasmids into 
vertebrates. This approach has generated substantial interest because of its 
speed, simplicity and ability to elicit both, humoral and cellular immune responses 
(Cox et al., 1993, Donnelly et al., 1997, Fynan et al., 1993, Robinson, 1997, 
Robinson & Torres, 1997, Wang et al., 1998). DNA-encoding HIV antigens were 
the first DNA vaccines against infectious diseases to be tested in humans 
(MacGregor et al., 1998). Clinical trials for several other DNA vaccines are 
currently in process, including HIV, malaria, Hepatitis B, influenza (Epstein et al., 
2005, Smith et al., 2005, Wang et al., 2005). In 2005, two DNA vaccines were 
licensed for use in animals (Lorenzen & LaPatra, 2005, Powell, 2004). 
However, researchers have to deal with technical problems concerning DNA 
vaccine potency. The reasons for the failure of many DNA vaccines to induce 
potent immune responses in humans have not been elucidated. However, it is 
assumed, that low levels of antigen production, inefficient cellular delivery of DNA 
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plasmids and insufficient stimulation of the innate immune system affect the 
potency of a DNA vaccine. 
 
Several strategies have been developed to increase the potency of DNA 
vaccines, as illustrated in Table 4. Investigations on different delivery systems, 
like electroporation and microparticle formulation showed an enhanced immune 
response compared to ordinary DNA transfection (Hermanson et al., 2004, 
Megede et al., 2006, Otten et al., 2005). DNA vaccines were applied together 
with adjuvants (CpG motifs, cytokines, chemokines) or in combination with a viral 
vector or a recombinant protein in a prime-boost regimen, showing increased 
immune response, compared to a simple DNA immunization. Priming with DNA 
was followed by boosting with recombinant adenovirus serotype 5 (rAd5) vectors 
(Casimiro et al., 2003, Shiver et al., 2002), recombinant modified vaccinia Ankara 
(rMVA) vectors (Amara et al., 2001), and recombinant vesicular stomatitis virus 
(rVSV) vectors (Egan et al., 2005). 
 
Table 4: DNA vaccination strategies of viral diseases that are currently in clinical or preclinical 
trials. 
1.3.3 SARS-COV AS MODEL: ANTIVIRAL AGENTS AND VACCINES 
During the SARS outbreak in 2002-2003, the spread of the disease was primarily 
controlled by strict quarantine protocols and patient isolation. In parallel multiple 
antiviral strategies have been proposed immediately. Several laboratories are 
involved in developing a SARS vaccine utilizing different types of SARS-CoV-
derived immunogens. 
Virus DNA vaccination strategy
HIV
Hepatitis B
Influenza
Plasmid DNA by particle-mediated epidermal delivery (i.e.; phase I)
DNA-prime + MVA vector-boost (Int.AIDS Vacc.Initiative & Oxf.Univ.; phaseI & II)
DNA encoding env/rev & gag/pol genes in combination with HAART 
DNA-prime encoding genes and boost with Ad5 (Merck & VRC; phaseI)
pDNA-HA or -NP, coadministration of a Schiffbase forming drug 
Reference
Smith J.M. et al, AIDS
Res.Hum.Retroviruses, 2005
Hejdeman B. et al, AIDS
Res.Hum.Retroviruses, 2004
Mascola J. et al,
J. of Virology, 2004
Rottinghaus S. et al,
Vaccine, 2004
Charo J. et al,
J. of Virology, 2004
Plasmid DNA (clinical trial) Ulmer J. et al,Science, 1993
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1.3.3.1 NAKED DNA 
The wild-type full-length S gene was used as a candidate DNA vaccine. The S-
protein under the regulation of a CMV promoter could induce the production of 
specific IgG antibodies against SARS-CoV in mice with a seroconversion ratio of 
75% after 3 times of immunization (Zhang et al., 2004). 
A DNA vaccine based on the codon-optimized S sequence has been shown to 
induce T cell and neutralizing antibody responses, as well as protective immunity, 
in a mouse model. Sequence optimization was required and a deletion of 13 
nucleotides in the cytoplasmic domain of the S protein yielded an improved 
immune response compared to the full-length protein. Protection was mediated 
by the humoral immune response (Yang et al., 2004). 
A plasmid encoding the full-length nucleocapsid protein (N) of SARS-CoV was 
used, because the N-protein is more conserved than the other structural proteins. 
The immune responses induced by i.m. immunization were evaluated in a murine 
model. The study showed that the N-protein of SARS-CoV not only is an 
important B cell immunogen, but also can elicit cellular immune responses (Zhao 
et al., 2005). These results indicate that the N-protein may also be of potential 
value in vaccine development against SARS-CoV. 
1.3.3.2 VIRAL VECTORS 
An adenoviral-based vaccine has been shown to induce strong SARS-CoV-
specific immune responses in rhesus macaques. A codon-optimized fragment of 
the S-protein (S1), the M-protein, and the N-protein were combined in an 
adenoviral delivery system to induce virus-specific immunity. Rhesus macaques 
were immunized i.m. with a combination of the three Ad5-SARS-CoV vectors and 
a booster vaccination after 4 weeks. The vaccinated animals all displayed 
antibodies against the S1-fragment and T-cell responses against the N-protein. 
All vaccinated animals showed strong neutralizing antibody responses to SARS-
CoV infection in vitro (Gao et al., 2003). 
In another study, a recombinant attenuated modified vaccinia virus, Ankara 
(MVA) expressing the S-protein of SARS-CoV was used. BALB/c mice were 
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infected i.n. or i.m. with MVA/S. Serum antibodies of the immunized mice showed 
neutralization of SARS-CoV in vitro. Passive transfer of serum from mice 
immunized with MVA/S to naive mice also reduced the replication of SARS-CoV 
in the respiratory tract after challenge, demonstrating a role for antibodies in 
protection (Bisht et al., 2004). 
An attenuated recombinant Vesicular Stomatitis virus (VSV-S) expressing the 
SARS-CoV S-protein was developed as well. Mice vaccinated with VSV-S 
developed SARS-neutralizing antibodies and were able to control a challenge 
with SARS-CoV performed one month or four months after a single vaccination 
(Kapadia et al., 2005). 
Furthermore the preparation of convalescent plasma, donated by patients who 
have recovered from SARS has been performed (Soo et al., 2004). 
In summary, none of these diverse strategies was efficient enough for full 
protection. Therefore it is important to find other strategies improving the humoral 
immune response. 
1.3.4 IMMUNE RESPONSES INDUCED BY DNA VACCINE 
DNA vaccines elicit efficient antigen specific antibodies and cytotoxic T cells in 
mice. Induction of a primary antibody response depends on the antigen and the 
number of immunizations. An immunization protocol with intervals helps to 
prolonge the presence of antigen and supports thereby both the primary and the 
secondary phases of antibody response. Application of DNA vaccines also 
induces a cytolytic T cell response. Upon injection of the naked DNA into the 
muscle (i.m.), the plasmid is taken up by myocytes and the antigen is 
synthesized. Only antigen-presenting cells can prime cytolytic T cells. Thus, if a 
non-antigen presenting cell takes up the DNA vaccine and produces the protein 
antigen, it must deliver the antigen to a professional antigen-presenting cell by a 
process called cross-priming, to induce cytolytic T cells (Srivastava & Liu, 2003). 
In general, i.m. injections predominantly rise a Th1 response with high titers of 
IFN-γ secreting T-cells providing help to cytotoxic T cells, and production of 
IgG2α antibodies. Plasmids encoding soluble antigens mostly induce Th2 type 
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responses, independent of the method or route of inoculation. The mechanisms 
by which DNA plasmids rise different types of T cell help is not well understood. 
A general overview of the immune response elicited by naked DNA is depicted in 
Fig. 4. 
Several studies with larger animals report that multiple doses of DNA in 
nonhuman primates (Amara et al., 2001) induce an immune response that is 
weak and short lasting. DNA priming and protein boosting have been shown to 
generally increase immune responses (Kong et al., 2005).  
 
 
 
 
Figure 4: Mechanism of action of plasmid DNAuptake. DNA uptake can be facile or facilitated. 
When expressed by APCs, the antigens can be processed and presented by major 
histocompatibility complex (MHC) molecules directly to naive T cells (direct priming). 
Alternatively, the antigens that are released from transfected cells (e.g. by apoptosis) can be 
internalized by surrounding cells like DCs for presentation by MHC molecules (cross priming). 
Certain CpG motifs can interact with TLR9 that is present on the membrane of endosomes of 
DCs and some other immune cells, thereby eliciting innate immune responses. The innate 
immune response can promote adaptive immune responses against the antigen produced by 
or transferred to DCs (adapted from Ulmer J. et al, Trends in Mol Med, 2006). 
 
1.3.5 ANIMAL MODEL 
Current animal models of SARS infection that faithfully mimic the human disease 
do not exist. It is presently not possible to evaluate relative vaccine efficacy; 
however, a variety of novel approaches, including adaptation of virus to different 
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species, the development of transgenic animals expressing the human ACE-2 
receptor, and the use of aged animals in challenge models, may contribute to this 
effort in the future (Kong et al., 2005). 
1.4 DIG’S AND GPI-ANCHORED PROTEINS 
The plasma membrane of eukaryotic cells is composed of hundreds of different 
lipid species. A spatial organization of these lipid enriched areas into discrete 
microdomains known as membrane rafts is thought to be important in the 
generation of distinct signal outputs (Parton & Hancock, 2004). These “islets” are 
also called lipid rafts, glycosphingolipid-enriched microdomains (GEMs) or 
detergent-insoluble, glycolipid-enriched complexes (DIGs). In contrast to the bulk 
membrane, these complexes are relatively resistant to solubilization with 
commonly used detergents such as Triton-X 100, NP-40 or CHAPS. DIGs are 
held together mainly by hydrophobic interactions between saturated fatty acid 
residues (Baumgartner et al., 2003, Horejsi, 2003). Most of the available data are 
based on analysis of the preparations obtained by density gradient 
ultracentrifugation of low-temperature detergent lysates. Because of their high 
lipid content, DIGs float to a low density during gradient centrifugation, which 
enables any associated proteins to be identified and distinguishes DIGs from 
detergent-soluble complexes (Simons & Ikonen, 1997). 
Recently a variety of new techniques (FRET, laser trap, single particle trap) have 
been used to study the cell surface, with the aim to resolve the size, distribution 
and dynamics of the DIGs without caveolaer characteristics (Laude & Prior, 
2004). Until now there was no substitute to see lipid rafts in the microscope 
convincing us of their existence and providing models for their organization and 
function. This is in contrast to other microdomains, like caveolae and clathrin-
coated vesicles, also localized in DIGs upon density gradient centrifugation and 
visible in the electron microscope, composed of 50-150nm invaginations. 
Characteristic protein components of DIGs include GPI-anchored proteins 
(Schroeder et al., 1994), many acylated proteins including Src family kinases 
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(Song et al., 1997), growth factor receptors, integrins (Baron et al., 2003) and 
cholesterol binding proteins including caveolin (Sargiacomo et al., 1993).  
1.4.1 GLYCOSYL PHOSPHATIDYL INOSITOL (GPI)-ANCHORED 
PROTEINS 
GPI-anchored proteins form a diverse family of molecules that include 
membrane-associated enzymes, adhesion molecules and receptors. Although it 
remains obscure why so many proteins are endowed with a GPI anchor, the 
presence of a GPI anchor does confer some functional characteristics to 
proteins: (1) it is a strong apical targeting signal in polarized epithelial cells 
(Brown D, cell, 1992); (2) GPI-anchored proteins can activate T cells of the 
immune system (Brown, 1993); (3) proteomic analysis revealed a 10-fold 
enrichment of signaling proteins in rafts versus total membrane (Foster et al., 
2003) and (4) they allow proteins an increased lateral mobility (Varki, A et al., 
Essentials of Glycobiology, 1999). 
It is possible to artificially target various proteins to membrane rafts by fusion of 
the required sequence for any modification by the GPI moiety (Cebecauer et al., 
1998, Premkumar et al., 2001). GPI-anchored proteins are translocated across 
the membrane of the endoplasmic reticulum (ER) and are initially anchored by a 
hydrophobic amino acid sequence. Immediately after synthesis, the hydrophobic 
sequence is cleaved on the luminal side of the ER (Boothroyd et al., 1981) and 
replaced by the GPI-anchor (Fig. 5). The efficiency of GPI-anchor addition is 
sequence-dependent (Moran & Caras, 1994). Once the signal is recognized the 
protein is cleaved and the new C-terminus is covalently linked to the preformed 
GPI portion (Menon et al., 1988). The topology of this process results in the 
localization of GPI-anchored proteins on the extracytoplasmic face of the 
membrane (Brown & Rose, 1992). 
In 2003, the Plasmodium falciparum antigen Pfs230 was conjugated to an amino 
acid sequence responsible for the GPI-anchor attachment, resulting in an 
improved immunogenicity in mice compared to the Pfs230 alone (Fanning et al., 
2003). 
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Figure 5: Attachment process of a GPI-anchor to the C-terminus of a 
protein. GPI-anchors are assembled in the ER and added to polypeptides 
anchored in the membrane by a C-terminal membrane-spanning region. 
The latter is cleaved, and the new CT is joined to the NH2-group of 
ethanolamine after translation is completed, leaving the protein attached to 
the membrane by the GPI-anchor (Varki, A et al., Essentials of 
Glycobiology, 1999). 
1.5 AIMS OF THIS PROJECT 
Classical vaccination methods have been shown to induce insufficient immune 
responses for certain viruses. Vaccination with naked DNA showed protection in 
mice experiments in a variety of studies. However, most vaccines remained 
inefficient in larger mammals. The ability of naked DNA to induce protective 
immunity needs to be improved. Until now, DNA plasmids have been modified by 
sequence optimization, expression enhancement and stimulation by adjuvants. 
Furthermore, administration of plasmid DNA in combination with other 
immunogens (prime-boost), generally resulted in an enhanced immune response. 
However, the protection for many approaches was still not satisfactory. 
In this study we investigated the improvement of DNA vaccination by two genetic 
modifications of the target antigen. (1) The exchange of the S-leader sequence 
by the influenza A HA-leader sequence (HASF). The HA-leader is known to 
enhance expression and glycosylation efficiency and translocation to the cell 
surface (Gething & Sambrook, 1982). (2) The TM and CP region of the S-protein 
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were replaced by the GPI-anchor attachment sequence. GPI-anchored proteins 
display an increased lateral mobility and appear in high density on lipid rafts. 
These modifications should allow an improved immune response through 
increased and optimized presentation of the target antigen on the cell surface. 
The SARS-CoV S-protein was used as antigen of interest. However, these two 
genetic modifications could be transferable to antigens of various other viruses, 
providing a new technology of DNA vaccination. 
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2 MATERIALS AND METHODS 
2.1 PLASMID CONSTRUCTION 
The S glycoprotein encoding cDNA was amplified by RT-PCR as three fragments 
using viral RNA as template (kindly provided by Prof. Doerr, Institute of Medical 
Virology, Frankfurt). 
The resulting three cDNAs were subcloned separately into the pVR1012. The 
gene fragments 1 and 2 were then inserted into pBluescript and excised as a 
single fragment using NotI and SalI restriction enzymes, fragment 3 was digested 
using Sall and BamHI. These cDNAs were then inserted into the NotI/BamHI 
sites of the pVR1012 plasmid to generate full-length S. Sequence analysis of the 
construct proved sequence identity with the Frankfurt1 (Fra1) isolate. 
All S constructs were cloned by PCR to encode a Flag-epitope at the C terminus 
for expression and localization analyses. The STOP codon was replaced by a 
Flag epitope encoding sequence followed by a STOP codon using primers 
(reverse primer: TGCGTAGGATCCTTATTTATCGTCATCGTCTTTGTAGTCACC 
TGTGTAATGTAATTTGACACCCTTGAGA). 
Forward primers amplified the haemagglutinin signal sequence of the influenza 
virus A/PR/8/34 (1: GTCGATGCGGCCGCCACCATGAAGGCAAACCTACTGGT 
CCTGTTATGGCACTTGCAGCTGCAGATGCAGACCGGTGCACCACTTTTGAT
GAT; 2: TCGATGCGGCCGCCACCAT), covering the sequence coding 16 amino 
acids and a reverse primer at the beginning of the S gene (CAATCAACAGCATC 
TGTGATTGTACC). The corresponding PCR product was inserted into the NotI 
and PstI sites of pBS(-)KS.SF. The sequence of HASF was subsequently cut with 
NotI and BamHI and ligated into pVR1012. As the GPI-anchor itself provides the 
characteristic sequence for membrane binding, we amplified the truncated, 
soluble S (sSF) as template for th PCR reactions. In a first step we amplified the 
3’-end of sS (forw: GGCCGTGATGTTTCTGATTTCACTG; rev: CAACGTGAAAC 
ACGTGTGCCCAGATAGAAGACGGGTAGTACCTGAACCTTTATCGTCATCGT
CTTTGTAGTCACC) coding for a portion of the GPI-anchor recognition 
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sequence. In a second step we completed the 3’-end to the whole coding region 
of this GPI-anchor sequence with TGCGTAGGATCCCTAAGTCAGCAAGCCCAT 
GGTTACTAGCGTCCCAAGCAAACCTGTCAACGTGAAACACGTGTGCCCA as 
reverse primer. The product was digested with BglII and BamHI and ligated into 
pBS(-)KS.SF and pBS(-)KS.HASF. 
2.2 CELL CULTURE 
Human embryonal kidney cells (HEK293T) were cultured at 37°C and 5% CO2 in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) containing 10% fetal calf 
serum (FCS). The cells were split every second day before reaching confluency. 
2.3 TRANSFECTION 
2.3.1 CALCIUM-PHOSPHATE TRANSFECTION 
HEK293 T cells were transfected with different plasmids using the Calcium-
Phosphate transfection method (Ref). Cells were seeded one day before 
transfection and the culture medium was changed 1h before transfection. 10cm 
plates at about 80% confluency were transfected with 10µg plasmid DNA diluted 
in 450µl dH2O and 50µl 2.5M CaCl2. 500µl 1xBBS (50mM BES, 280mM NaCl 
and 1.5mM Na2HPO4 adjusted to a pH of 6.94) is added drop wise while 
vortexing the tube. DNA precipitates were incubated at room temperature for 
20min and added drop wise to the cells. Cells were incubated at 37°C and 5% 
CO2 for 18h and fresh medium was added. Analyses were performed 48h after 
medium change. 
2.3.2 LIPOFECTAMINE TRANSFECTION 
1h prior to Lipofectamine-transfection the medium of the cells was changed and 
fetal calf serum (FCS)-free medium (D-MEM, Gibco) was added. DNA was 
diluted in OptiMEM® (Gibco). LipofectamineTM 2000 (Invitrogen) was diluted in 
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OptiMEM® and incubated for 5min at room temperature. The diluted DNA and 
LipofectamineTM 2000 were combined, incubated for 20min at room temperature 
and added to the cells. Medium was changed 4h after transfection and D-MEM + 
10% FCS (Brunschwig) was added. 
For a 10cm plate the following amounts were used: 10µg DNA in 1.5ml Opti-
MEM® and 30µl LipofectamineTM2000 in 1.5ml Opti-MEM®. 
2.4 PROTEIN ASSAY’S 
2.4.1 PLASMA MEMBRANE EXTRACTION 
One 10cm plate of HEK 293T cells were used per condition to isolate plasma 
membrane fractions using a protocol published by Bogan et al. (Bogan J, mol cell 
biol, 2001). Cells were rinsed twice with ice-cold phosphate-buffered saline (PBS, 
Gibco) and cells were lysed in TSD buffer (20mM Tris-HCl, 250mM sucrose, 
protease inhibitors). A preclearing spin was performed two times at 800g for 
5min, the supernatant was collected and centrifuged at 16’000g for 20min. The 
pellet was resuspended in 1ml 1xTSD and pelleted once more. The pellet was 
then resuspended in 1ml of 1xTSD and layered on 2ml of a 1.12 M sucrose 
cushion, followed by centrifugation at 95’000g for 65min, the interface was taken 
and the samples were resuspended in TD buffer (20mM Tris-HCl, protease 
inhibitors). The resuspended fractions were again centrifuged at 60’000g for 
10min and the pellet resuspended in NETN-buffer (20mM Tris-HCl pH7.5, 
100mM NaCl, 1mM EDTA, 0.5% NP-40 and protease inhibitors). Protein 
concentration was measured and aliquots of the lysates were stored at –20°C. 
2.4.2 LIPID RAFT EXTRACTION 
Lipid rafts were prepared by detergent extraction on ice and flotation on sucrose 
gradients using a protocol previously described (Baumgartner et al, blood, 2003). 
About 2x107 HEK293 T cells were rinsed with PBS, and lysed in 300ml of 
metabisulfite-Triton-X 100 (MBS-T) buffer (25mM MES, 150mM NaCl with pH6.5, 
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0.5% Triton X-100, protease inhibitors) for 30min on ice. The lysates were 
scraped from the dish with a rubber policeman and a sucrose gradient was 
produced. Therefore an equal volume of 85% sucrose solution in MBS (MBS-T 
without Triton X-100) was gently mixed with the cellular lysates to generate a 
42.5% solution at the bottom of a SW55ti ultracentrifugation tube. The 
lysate/sucrose mixture was subsequently overlaid on ice with 2ml of a 35% 
sucrose solution (diluted in MBS) and 1ml of 5% sucrose solution (diluted in 
MBS) containing protease inhibitors. Ultracentrifugation was performed in a 
Beckman SW55Ti rotor at 47000rpm (200’000g) for 18h at 4°C. A visible band at 
the interface 5/35% of the sucrose gradient represented the DIGs. Fractions were 
taken out at this interface and at the bottom of the tube, where soluble proteins 
fractionate. Protein concentration was measured and aliquots of the lysates were 
stored at –20°C and the composition of the DIGs was analyzed by Western blot. 
2.4.3 IMMUNOFLUORESCENCE 
HEK293T cell monolayer was rinsed twice with cold PBS before fixing them with 
3% Paraformaldehyde for 15min at room temperature. After three more washing 
steps with PBS cells are permeabilized in 0.25% Triton X-100 for 5min at RT. 
Permeabilized cells are washed 3x 5min with PBS and transferred on a plastic 
box covered with a hydrophobic surface. The primary AB was added in a small 
volume (35µl for one cover slip) of an appropriate antiserum dilution (anti-FLAG 
M2, mouse; 1:500) and incubated for 60min at RT. The cover slips are washed 
three more times with PBS and 35µl of the secondary antibody is applied (dilution 
1:100) and incubated for 30min. at RT. The cover slips are finally rinsed 3 times 
with PBS and mounted with cell side down onto microscope slide. As mounting 
solution either use Mowiol (Hoechst). In order to allow slides to dry, they are 
stored o/n before viewing under the microscope. Longer storage of the cover 
slips in the dark at 4°C. 
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2.5 ANTIBODIES AND WESTERN BLOTTING 
For Western blotting, transfected cells were diluted in SDS Laemmli buffer and 
boiled at 95°C for 5min-10min. Samples were electrophoresed in SDS-7.5% 
polyacrylamid gels (SDS-PAGE), and the proteins were transferred onto 
nitrocellulose membranes (HybondTM-ECLTM). Membranes were blocked with 5% 
skim milk TBS/Tween buffer (20mM Tris-HCl pH=7.5, 0.5 M NaCl, 0.05% Tween 
20) and mouse anti-Flag (Sigma), rabbit anti-caveolin-1 (Santa Cruz 
Biotechnology, Inc.) or mouse anti-human transferrin receptor (Zymed 
Laboratories Inc.) antibodies were diluted 1:500 in 5% skim milk TBS/Tween 
buffer and membranes were incubated for 1h at RT. Membranes were 
subsequently washed and incubated with either horseradish peroxidase-
conjugated sheep anti-mouse or donkey anti-rabbit (Amersham Biosciences) as 
secondary antibody for 1h at RT. Chemiluminescence detection was performed 
according to the manufacturer’s protocol (ECL detection kit, Amersham 
Biosciences). 
2.6 MICE 
Six to eight week old female C57BL/6 mice were injected intramuscularly with 
100µg of DNA, 50µg into each leg. Mice were immunized four times in a three-
week interval and blood samples were taken two weeks after each immunization. 
2.7 EVALUATION OF MICE SERA 
2.7.1 SARS-COV INDIRECT IMMUNOFLUORESCENCE TEST 
25µl of 1:50 diluted serum is pipetted on each rectangle of the reagent tray. The 
BIOCHIP is applied on the reagent tray. The serum is incubated for 30min with 
the cells at room temperature. BIOCHIP is flushed with PBS-Tween and 
incubated for 5min in PBS-Tween in a cuvette while shaking. 20µl of 1:50 TRITC 
donkey anti-mouse antibody are pipetted on each rectangle of the reagent tray 
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and the BIOCHIP is applied and incubated for 30min at RT. Cells are then 
washed with PBS-Tween and incubated for 5min in PBS-Tween in the cuvette 
while shaking. The cover slips were evaluated under the fluorescence 
microscope. 
2.7.2 ELISA WITH RECOMBINANT SOLUBLE S PROTEIN OF SARS-COV 
Sera from 25 C57Bl/6 mice were used to set up a baseline for the S protein 
ELISA-based IgG antibody test. Each well of a Nunc immunoplate (Roskilde, 
Denmark) was coated with recombinant soluble, FLAG-tagged Spike protein 
(diluted 1:100) over night at 4°C and then blocked for 3h in PBS with 2% skim 
milk. The serum samples were 1:100 diluted and added to the wells of the coated 
plate in a total volume of 100µl and incubated at RT for 2h. After three washes 
with 0.05% Tween 20 in PBS, 100µl of diluted horseradish peroxidase-
conjugated sheep anti-mouse IgG (1:10’000) was added to the wells and 
incubated at RT for 1h. After washing with washing buffer three times, 100µl of 
diluted 3,3’,5,5’-tetramethylbenzidine (Zymed Laboratories, Inc.) was applied to 
each well and incubated at RT for 20min. 50µl of 1 M H2SO4 was added, and the 
absorbance at 450nm and 540nm of each well was measured. Each sample was 
tested in triplicate, and the mean absorbance for each serum was calculated. 
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3 RESULTS 
3.1 CHARACTERIZATION OF HA-TAGGED AND GPI-
ANCHORED S-PROTEINS COMPARED TO WILD TYPE 
SF PROTEIN 
The wild type S-protein was genetically modified by two different strategies. (1) 
The S-protein leader sequence was exchanged by the influenza A/PR/8/34 HA 
leader sequence. The first 16 AA of the S-protein were replaced by the first 16 
AA of the HA protein. The construct was named HASF. (2) The transmembrane 
(TM) and cytoplasmic (CP) domain of SF and HASF were replaced by the 
sequence for the GPI-anchor attachment. 
The expression of the different SARS-CoV S-proteins was characterized by 
transfection of HEK293 T cells with plasmids encoding the indicated constructs 
(depicted in Fig. 6). All constructs included a Flag epitope, to allow antibody 
detection, as no commercially available antibody against the S-protein existed. 
The DNA sequence of each gene was confirmed. The cell lysates were analyzed 
by Western blotting. As shown in Fig. 7 lysates from 293T cells transfected with 
the different vectors revealed a protein band with a size of approximately 
190kDa, which is the predicted size for the S-protein. 
 
 
Figure 6: Schematic representation of the wild type SARS-CoV S-protein 
and the modified variants. Structures of the cDNAs used; SF: full length 
with a Flag-tag at the CT; HASF: S leader is replaced by the influenza HA 
leader; SFG: TM- and CP-region of the S-protein were replaced by the 
sequence for GPI-anchor; HASFG: HA leader and GPI-anchor. 
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The expression of SF was very weak, compared to HASF, and the expression 
efficiency was observed to be higher for HASFG than for SFG (Fig. 7). This led to 
the conclusion that the HA-tag might have an effect on the expression efficiency. 
According to their molecular weight, the S-GPI-fusion proteins run at a slower 
mobility than the full-length constructs (Fig. 7). This was explained by the 
exchange of the TM- and the CP-regions by the GPI-anchor sequence, which 
was encoded by a shorter sequence (depicted in Fig. 6). 
 
 
Figure 7: Expression of recombinant proteins; expression was 
determined by total protein extraction followed by Western blot analysis 
against the Flag-tag. S represents the S-protein without a tag, used here 
as a negative control, and FMxA stands for the MxA protein with a Flag 
epitope as positive control. Actin was detected as loading control. 
 
An immunofluorescence assay with all different constructs showed the protein 
expression in individual cells (Fig. 8). Cells were permeabilized and expression of 
SF, HASF, SFG and HASFG in the whole cell was detected with an antibody 
against the Flag-epitope. 
The expression levels of the individual constructs show significant differences in 
both analyses, western blotting and immuno-fluorescence. The expression level 
of HASF was higher than of SF, confirming the result from Fig. 8, identifying an 
effect of the HA-tag on the expression efficiency. The SFG-expression level was 
also inferior compared to HASFG, possibly because of the positive effect of the 
HA-tag. SFG displayed a higher expression level than SF, suggesting a positive 
impact of the GPI-anchor attachment sequence on the expression efficiency. In 
conclusion we state an influence on the expression level of the S-protein with 
exchange of any of the two genetic modifications used in this study. The HA-tag 
and the GPI-anchor signal sequence improved the expression of the protein and 
increased its potential as an antigen. Our finding was consistent with previous 
studies, which identified an increase in expression level by the influenza HA 
signal sequence on (Chao et al., 1987, Gething & Sambrook, 1982). 
 31
 
  
Figure 8: The expression of the various constructs shown by immunofluorescence assay with 
HEK293 T cells transfected with the plasmid encoding for the indicated protein. Cells were 
observed with a Zeiss Microscope equipped with a x40 magnification, 1.3 numerical aperture 
oil immersion lens. 
 
3.2 ENHANCED EXPRESSION OF HA-TAGGED SF 
3.2.1 WESTERN BLOT ANALYSIS 
To confirm that the HASF construct showed an improved expression at the cell 
surface, a plasma membrane (PM) extraction was performed and the protein 
production was analyzed by Western blotting. To test overall expression levels of 
SF and HASF, we extracted total protein, as depicted in Fig. 9A. Quantitative 
analysis of the whole lysate showed a stronger expression of HASF compared to 
SF. To demonstrate the appearance of SF and HASF at the cell surface, equal 
amounts of proteins were loaded on the gel. SF and HASF both appear at the 
plasma membrane (Fig. 9B). We observed an increased amount of HASF at the 
plasma membrane, compared to SF. From these results we cannot conclude 
whether the difference between HASF and SF is higher in the PM-localization 
blot (Fig. 9B) than the total protein-blot (Fig. 9.A). Only a significant difference in 
the difference of expression level between HASF and SF of the two blots would 
confirm an effect of the HA-tag as a signal sequence. Ultimately the effect is 
explained by the altered sequence as sequence optimizing measure. However, 
the amount of HASF at the plasma membrane is significantly enhanced 
compared to SF, suggesting that HASF would be a more potent antigen than SF. 
The bands with different mobility in Fig. 9B represent the multimeric and the 
monomeric form of the SF and HASF, respectively. Fig. 9B shows the same blot 
with the human transferrin receptor antibody (hTfR), which serves as loading 
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control and marker for membrane fractions. As shown in Fig. 9.B calnexin was 
detected as a marker for the ER, giving evidence that the plasma membrane 
extraction was not contaminated with membranes of the ER. 
 
A: B: 
Figure 9: Localization of the S-protein mutants SF and HASF to the plasma membrane. 
Western blot analysis of HEK293 T cells transfected with the mammalian expression vector 
pVR1012 containing the desired fragment. Detection of the S-constructs by the Flag-tag. A: 
Total protein expression of SF and HASF. B: Plasma membrane extraction to show 
localization of SF and HASF. Detection of hTfR, loading control. Detection of calnexin, marker 
for the ER. 
3.2.2 BIOINFORMATIC ANALYSIS 
A bioinformatic study using the prediction software PSORT (Nakai & Horton, 
1999, Nakai & Kanehisa, 1992) revealed a similar localization pattern of HASF 
and SF. PSORT is a program for detecting sorting signals in proteins and 
predicting their subcellular localization. Therefore it requests a full-length amino 
acid sequence and its sequence origin (gram-positive or gram-negative bacteria, 
yeast, animal or plant). PSORT functions with a simple algorithm -the k-nearest-
neighbor method (Horton & Nakai, 1997). The predictive accuracy was assessed 
by ten-fold cross-validation, using 1531 Saccharomyces cerevisiae sequences 
encoded in nuclear DNA. The total accuracy of the prediction is 57% for these 
proteins. 
As illustrated in Fig 10, SF and HASF were predicted to localize to intracellular 
membranes. 45% of the proteins localize in the ER, 33% in the Golgi and only 
22% to the plasma membrane. This distribution is consistent with our previous 
data of the western blot analysis. The influenza glycoprotein HA was transported 
efficiently to the cell surface. Therefore, we compared the localization pattern of 
HA with the SARS-CoV S-proteins. HA was predicted to appear in equal amounts 
(33%) in the ER, the Golgi and the plasma membrane. Localization to the PM 
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was thus more efficient than of SF and HASF, suggesting the HA-sequence to 
contain additional protein signals relevant for the sorting to the cell surface. Both 
constructs will be used for a DNA vaccination study in mice. 
 
 
Figure 10: Cellular distribution of SF and HASF compared to the 
influenza A HA protein, using the PSORT prediction software from 
Kent Nakai (http://psort.ims.u-tokyo.ac.jp) 
3.3 ISOLATION OF GPI-ANCHORED S-PROTEINS IN 
DIG’S 
3.3.1 WESTERN BLOT ANALYSIS 
Membrane rafts, defined as lipid-protein complexes insoluble in cold detergent 
solutions, because of their high lipid content and thus low buoyant density, can 
be isolated by density gradient ultracentrifugation. The low density allows DIGs to 
float in sucrose gradients upon extraction with Triton-X 100 at 4°C. This method 
allowed distinguishing between detergent-insoluble and detergent-soluble 
fractions to determine the co-fractionation of the overexpressed S-GPI proteins 
with other DIG-residing proteins. We compared the localization pattern of the S-
GPI fusion proteins with the SF-protein and observed that GPI-constructs 
appeared in the detergent-insoluble fraction (DIF; Fig. 11). SF was not detected 
in this fraction, but in the detergent-soluble fraction (DSF; Fig. 11). The protein 
level of SFG in the DIF was lower than that of HASFG, suggesting a higher 
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amount of HASFG localizing in DIGs. However, total protein extracts showed a 
higher level of HASFG than SFG (Fig. 11). We further conclude, that this 
difference in localization to the DIGs originates from the HA-tag. The HA-tag is 
responsible for higher expression efficiency and thus more protein is available to 
be embedded into DIGs. The fraction of the detergent-soluble proteins showed 
the expression of the S protein and to a lower level of the S-GPI fusion proteins 
(Fig. 11). 
SFG and HASFG were found in monomers and oligomers after the denaturing 
process. From this gel we could not conclude whether the band of a lower 
mobility represented a dimer or a trimer. The band with the oligomers indicates 
the high protein stability of the S-protein and the GPI-anchored S-protein 
complexes. Interestingly, the S-protein only appeared as oligomer, compared to 
the S-GPI fusion proteins, suggesting that the original S-protein sequence 
displayed a higher stability than the S-proteins with the GPI-anchor. The TM and 
CP region of the S-protein seemed to improve the stability of this protein. Fig. 11 
showed the detection with anti-caveolin-1 and anti-hTfR as marker for DIGs and 
detergent-soluble membrane respectively. This suggested that the membranes 
were enriched for the marker proteins. 
 
 
Figure 11: Isolation of GPI-anchored S-proteins in DIGs. Extraction of 
the detergent-insoluble fraction (DIF) and the detergent-soluble fraction 
(DSF) followed by Western blot analysis. SFG and HASFG were 
shown to co-localize in DIF. 
3.3.2 BIOINFORMATIC ANALYSIS 
In order to compare the sorting of the S-proteins attached to a GPI-anchor and 
the full length S-protein, a bioinformatic analysis was performed using the 
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PSORT prediction software (Fig. 12). SFG as well as HASFG were predicted to 
be transported to the cell surface to 67%. 33% remained to equal parts in the 
endoplasmic reticulum, vacuolar membranes and in mitochondria. The prediction 
with PSORT distinguished the S-protein sorted by the original pathway from the 
GPI-anchored S-protein by 45% (SF was sorted 45% less efficiently to the cell 
surface). 
SFG as well as HASFG displayed an equal distribution to the different cellular 
compartments. This data indicated, that the sorting was not dependent on the S 
and the HA signal sequence at the N-terminus, but entirely dependent on the 
GPI-anchor attachment. In agreement we determined an enhanced expression of 
HASFG, compared to SFG and identified the presence of both recombinant 
proteins in DIGs. Therefore we speculate for an increased presentation of SFG 
and HASFG to the immune system. Both constructs will be used for a DNA 
vaccination study in mice. 
 
 
Figure 12: Cellular distribution of SFG and HASFG compared to the SF 
mutant, using the PSORT prediction software from Kent Nakai 
(http://psort.ims.u-tokyo.ac.jp). 
3.4 VACCINATION WITH HASF, SFG AND HASFG 
SIGNIFICANTLY IMPROVED THE IMMUNE RESPONSE 
In order to test the efficiency of the different S-protein constructs in vivo, mice 
were immunized with plasmid DNA (Fig. 13). Therefore, five mice per construct 
were immunized four times i.m. with a three-week interval with plasmid DNA 
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encoding for SF, HASF, SFG or HASFG. Five mice that received the empty 
vector served as background control. Serum samples were collected 7 days after 
each immunization. An ELISA was established to evaluate the humoral immune 
response evoked by the DNA encoding for SARS-CoV S-protein mutants, as 
described in materials and methods. Soluble S-protein (sSF) was chosen as 
coating material in the ELISA. Therefore HEK293T cells were transfected with 
pVR1012sSF and lysates were collected. 
 
 
Figure 13: Protocol for the immunization of C57Bl/6 mice with the S-protein mutants indicated. 
3.4.1 ELISA 
ELISA analysis was performed to detect the S-protein specific antibodies of the 
sera. As shown in Fig. 14 all DNA plasmids produced antibodies binding the 
coating protein sSF. The immune response generated following immunization 
with p-SF was on the background level, together with the sera tested of the mice 
immunized with the empty vector. The antibody titer of mice immunized with p-
HASF showed a two fold induction compared to the serum of the mice 
immunized with p-SF. Furthermore, p-HASFG induced a higher humoral immune 
response than p-SFG (0.5 versus 0.3). The ELISA results indicated, that p-
HASFG displayed the best antibody response in comparison to the other vectors. 
p-HASF and p-SFG induced an equal level of S-protein specific antibodies. 
These data were consistent with the results from the expression analysis. 
Therefore, the improved antibody response of p-HASF compared to p-SF could 
be due to the enhanced expression of p-HASF shown in Fig. 9A and 9B. The 
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introduction of the GPI-anchor sequence was shown to be comparable with the 
introduction of the HA-tag. Both genetic modifications led to a similar 
improvement of the humoral immune response (comparing p-HASF and p-SFG). 
p-HASFG, including both genetic modifications, was the strongest antigen. 
 
 
Figure 14: Immunization with SFG and HASFG significantly improved the immune 
response in C57BL/6 mice. Analysis of the sera by ELISA: Sera of C57BL/6 mice after 
the fourth i.m. immunization with the indicated expression plasmid encoding for the S-
protein variants. The mice sera (1:100 diluted) were applied in triplicates and 
incubated for 1h. Anti-mouse antibody coated with HRPO was added in a 1:10‘000 
dilution. Absorbance was measured at 450nm and 540nm. The relative absorbance of 
4 mice was substracted from the absorbance of the serum of non-immunized mice. 
Student t-test revealed: *p<0.05. 
3.4.2 INDIRECT IMMUNOFLUORESCENCE ASSAY 
In order to confirm the data obtained by the ELISA, an immunofluorescence 
assay was performed (Euroimmun AG). After the fourth i.m. immunization, serum 
samples of mice, were examined in a 1:50 dilution. The sera were applied to 
monkey cells, either infected or non-infected with SARS-CoV. Serum from a 
SARS-CoV infected patient served as positive control and serum from a healthy 
patient as negative control. Cells treated with positive control serum (hSARS-
CoV) showed specific staining compared to cells treated with negative control 
serum (hmock). The fluorescent particles detected, were defined to be unspecific 
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(i.e. cell debris), as similar fluorescence signals were found on the slide with non-
infected cells. Furthermore no compartmentalization and typical morphology 
could be observed. The serum from mice immunized with p-SF, p-HASF, p-SFG 
and p-HASFG showed specific fluorescence in some of the infected cells. Fig 
15F and 15G showed an enhanced background staining. Cells treated with 
serum of p-HASFG-immunized mice showed augmented fluorescence, compared 
to the cells of p-SF-, p-HASF- or p-SFG-immunized mice. The non-infected cells 
did not provide the same staining for every slide. This might be explained by anti-
mitochondrial or anti-nuclear antibodies (might be the case for mSFG and 
mHASFG, respectively) contained in the mice sera. 
 
 
Figure 15: Sera of mice immunized with SF, HASF, SFG and HASFG showed specific 
interaction with SARS-CoV infected cells in an indirect immuno-fluorescence test 
(Euroimmun AG). Serum (1:50 dilution) was applied to the BIOCHIP containing SARS-CoV 
infected and non-infected cells. Upper panel: non-infected cells; lower panel: infected cells. 
Cells were stained with TRITC anti-mouse. Serum of a healthy patient and serum of a 
SARS-CoV infected patient served as negative and positive control, respectively; mSF-
mHASFG are immunofluorescence pictures representing the cells incubated with sera of 
mice immunized with p-SF, p-HASF, p-SFG or p-HASFG. 
 
The immunofluorescence data were consistent with the data we obtained with the 
ELISA. However we could not quantify a difference in fluorescence between SF- 
and HASF-serum and between SFG- and HASFG-serum. Together with the data 
extracted from the ELISA we identified the highest titer of SARS-CoV specific 
antibodies in the serum of mice immunized with p-HASFG. This finding confirmed 
our previous results, that both tags were required to significantly improve the 
antibody response. 
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4 DISCUSSION 
The S-protein was identified to be the main antigen of SARS-CoV (Rota et al., 
2003). Therefore we chose it as antigen in a DNA vaccine. DNA vaccinations 
have been tested for induction of cellular and humoral immune response against 
the SARS-CoV S-protein. Yang et al. (Yang et al., 2004) demonstrated that a 
DNA plasmid encoding the codon-optimized S-protein induced neutralizing 
antibodies, as well as a T-cell response. Protection from the SARS-CoV 
challenge in a murine model was mediated by the humoral immune response. 
Transfer of mice sera was sufficient to confer protection against SARS-CoV 
(Zhang et al., 2004). Therefore, DNA vaccination approaches with the SARS-
CoV S gene might result in protection. Despite the fact that the S-protein 
represents the main target for vaccination, it is also known to be a weak antigen 
(Xiao et al., 2003). We therefore anticipated (1) the retention of the S protein 
through a retention signal, by a so far unknown mechanism (Lontok et al., 2004). 
(2) The interaction of the S-protein with other viral proteins withholding the S-
protein inside the cell, as determined for S-proteins of other coronaviruses 
(Nguyen & Hogue, 1997). In this study we tried to overcome these limitations by 
genetic modifications. 
S-proteins of other coronaviruses were identified to contain specific retention 
signals. Several responsible signal sequences were discovered. The infectious 
peritonitis virus S-protein was reported to be intracellularly retained in the ER 
because of its structure containing a dilysine motif (Vennema et al., 1993). The 
porcine coronavirus (Transmissible Gastroenteritis virus; TGEV) displayed a 
newly discovered sorting signal for intracellular localization (Schwegmann-
Wessels et al., 2004). Retention of the coronavirus S-protein generally appears 
reasonable, considering the virus particle formation of this virus species 
intracellular. The budding process occurs at the cis-Golgi network/endoplasmic 
reticulum-Golgi intermediate compartment (ERGIC) (Hauri et al., 2000). This 
hypothesis is supported by the fact, that intracellular retention of the viral 
membrane proteins delays the time point of recognition of the infected cell by the 
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humoral and cellular defense systems. However, an increased level of the 
surface S-protein could promote syncytium formation and direct cell-to-cell 
spread of the infection (Lontok et al., 2004). The aim of this study was to optimize 
the synthesis, to increase the presentation of the S-protein as an antigen on the 
cell surface. In this study, the presentation of the S-protein on the cell surface 
was improved by two sequence modifications. 
In order to enhance the expression and transport efficiency to the cell surface, 
the 5’-S-leader sequence at the amino terminal was replaced by the HA-leader 
sequence. Previous studies showed a different transport behavior for the full 
length HA-protein and the HA-protein missing the leader sequence. The HA-
protein without a signal sequence was produced at low levels, located 
intracellularly, and was not glycosylated (Gething & Sambrook, 1982). The HA 
leader was thus increasing the transport efficiency through the ER, whereas 
truncated HA remained predominantly in the ER (Chao et al., 1987). In this study, 
the exchange of the S-leader sequence by the HA sequence (HASF), improved 
the overall expression efficiency in cell culture. If the over-expression of an 
intracellularly retained protein has exceeded a threshold value, the cellular 
interaction partners become saturated and are not able to retain the excess 
amount of the protein. This phenomenon has been reported for proteins that are 
retained intracellularly, e.g. in the endoplasmic reticulum-Golgi intermediate 
compartment (Hauri et al., 2000). This has to be taken in account for evaluation 
of transport efficiency caused by over-expression instead of specific targeting. 
We demonstrate an improved expression of HASF compared to SF and an 
increased expression of HASF at the plasma membrane compared to SF. This 
experimental result was consistent with the data of the studies mentioned above. 
The sequence of the HA leader was examined to be responsible for improved 
expression. Mice immunized with the DNA plasmid encoding for HASF (p-HASF) 
showed an enhanced S-specific antibody titer, compared to mice immunized with 
p-SF. We could not determine, whether the increased localization of HASF to the 
cell surface was due to the potency of the HA-leader sequence as a signal 
sequence, or whether the HA-tag was responsible for an enhanced expression 
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level due to optimized nucleotide sequence and thus enhanced translation 
efficiency. The insertion of the HA-leader sequence appeared to have a limited 
effect on trafficking of the S-protein, as the difference between SF and HASF 
expression in total protein extracts and PM-extracts was not significantly 
different. This observation was consistent with the data of Yang and co-workers 
(Yang et al., 2004). In that study, the SARS-CoV S-protein leader sequence was 
exchanged by the leader sequence derived from the interleukin-2 gene (IL-2). 
The IL-2 leader sequence did not alter the expression behavior of the S-protein 
(Yang et al., 2004). The data of the bioinformatic study using the software 
PSORT, did not determine any difference in the sorting of SF and HASF. The 
same analysis determining sorting of the GPI-anchored S-proteins revealed 
equal distribution of SFG and HASFG to diverse cellular compartments. This is 
an indication for the minor relevance of the leader sequence in trafficking. Thus, 
retention signals of the S-protein other than the leader sequence could be 
responsible for the weak difference in redistribution between SF and HASF, 
observed in Fig. 9A and 9B. Alternatively it might be an artefact. Lontok et al. 
identified a dibasic (KXHXX) intracellular localization signal at the very C-terminal 
amino acids, preceding the STOP codon of the SARS-CoV S-protein detected by 
the GPI-anchor attachment (Lontok et al., 2004). 
The HA-protein itself is known to be a stronger antigen than the S-protein (Xiao 
et al., 2003). We speculate that the improvement of the S-protein as an antigen 
originates in the expression efficiency and the following improved presentation at 
the plasma membrane and thus to the immune system. 
There is no information on viral interaction partners of the SARS-CoV S-protein 
during protein synthesis or virus assembly, which could affect the retention of the 
S-protein in an intracellular compartment. Nevertheless, this lack of information 
should be taken into account, since complex formation between the M-protein 
and the S-protein were shown to have an effect on the translocation of the S-
proteins of other coronaviruses (Nguyen & Hogue, 1997). The interaction with 
other proteins may be important for the antigen presentation. Future analysis of 
these interactions should address the hypothesis comprehensively. The impact of 
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complex formations between the S-protein and cellular proteins was not 
examined in this study. Viral proteins were not considered as interaction partners 
of the S-protein, due to the lack of the other viral proteins in this vaccination 
strategy. 
 
In order to facilitate the transport of the S-protein to the cell surface, we also 
designed an S-protein mutant in which the transmembrane and the cytoplasmic 
domain were exchanged by the sequence responsible for GPI-anchor 
attachment. This modification should allow targeting to lipid rafts (Brown & 
Waneck, 1992, Brown, 1992, Brown & Rose, 1992) and therefore increased the 
presentation on the cell surface. In addition it should prevent the involvement of 
the predicted dibasic retention signal. Furthermore, mice immunized with the 
truncated S-protein lacking the last 13 nucleotides, led to improved immune 
responses compared to the full length construct (Yang et al., 2004). 
The attachment of the GPI-anchor sequence enabled the extraction of the S-
protein from detergent-insoluble fractions, which included lipid rafts. Lipid rafts 
represent micro-domains presenting proteins in high density. Moreover these 
proteins are known to show an increased lateral mobility and an extended half-
life of cell surface proteins (Premkumar et al., 2001). GPI-anchors are thus 
thought to potentate the possible immune response of an antigen (Bohme & 
Cross, 2002). Caveolae, the second kind of lipid-enriched membrane domains, 
display a highly organized structure containing caveolin-1 and are therefore 
visible under the electron microscope (50-70nm; Palade, 1953), compared to lipid 
rafts which do not contain any structures providing contrast. Most of the data 
obtained until now demonstrated the functional roles of lipid rafts based on 
membrane solubilization in suitable detergents and isolation of the lipid-enriched 
detergent resistant microdomains by density gradient ultracentrifugation. Only 
recently there have been major improvements in visualization of lipid rafts (Prior 
et al., 2003). Due to technical difficulties we could not perform lipid raft detection 
by microscopy. However, recently published data did show the existence of lipid 
rafts in living cells and also the presence of GPI-anchored proteins in these rafts. 
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Our results are interpreted taking in account the recent findings (Monastyrskaya 
et al., 2005, Wilson et al., 2004). 
Our experimental data showed that the S-GPI proteins were associated with the 
detergent-insoluble membranes (DIF). The GPI-anchored S-proteins were thus 
present in lipid rafts. The preparation of DIFs by sucrose gradient flotation led to 
the co-extraction of caveolin-1, a characteristic protein of caveolae. The 
extraction of DIGs does not allow spatial discrimination of the two microdomain 
subtypes, lipid rafts and caveolae. The presence of caveolin-1 in DIF can be 
explained by the co-extraction of lipid rafts and caveolae by detergents and 
analysis by the sucrose gradient ultracentrifugation method. As shown in Fig. 10 
the DIF fractions also contained caveolin-1. SFG as well as HASFG were 
detected in DIFs. SF did not show any co-localization with the GPI-anchor 
proteins in the DIGs, suggesting that the localization of the S-protein mutants in 
lipid rafts is entirely dependent on the GPI-anchor. Our experimental data were 
consistent with the data of other research groups, where GPI-anchored proteins 
were identified in lipid rafts (Bairoch & Apweiler, 1997, Brown & Waneck, 1992, 
Brown, 1992, Brown & Rose, 1992). SFG and HASFG also appear in the 
detergent-soluble fraction (DSF; Fig. 10). The presence of SFG and HASFG in 
the DSF could be explained by the over-expression. Over-expression of 
secretory proteins has been shown to affect the trafficking of these proteins (Nal 
et al., 2005). This may explain the presence of exogenous SFG and HASFG in 
this fraction. 
SF as well as SFG and HASFG appeared as multimeric complexes despite 
denaturation by SDS-treatment. The oligomerization of the SARS-CoV S-protein 
was found to be very stable. The oligomers of the S-protein with the original TM 
and CP region displayed resistance to denaturating conditions as SDS and β-
mercaptoethanol treatment. The stability of the SF-oligomers was higher than 
that of the GPI-anchored S-oligomers. Further experiments are required to show 
the improved stability of these proteins in vivo. 
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Our experimental data of mice sera were consistent with the results obtained by 
the cell culture study. The difference in the immune response between SF and 
HASF, and between SFG and HASFG, can be explained by the variations in the 
expression level, which might be comparable to the expression level observed in 
cell culture. In cell culture we have shown a higher protein expression for HASF 
than for SF and the same for HASFG and SFG. The enhanced expression was 
shown to be consistent with the improved immune response of HASF and 
HASFG compared to SF and SFG, respectively. The antibody titer of p-HASF 
immunized mice was twice as high as the titer of mice immunized with p-SF. The 
combination of the HA leader sequence and the GPI-anchor improved the 
expression and possibly also the antigen presentation, compared to the S-
proteins containing only either the HA leader sequence or the GPI-anchor, in 
vitro. This subsequently led to a stronger humoral immune response in mice. The 
presence of both modifications in the S-protein (HASFG) increased the antibody 
titer three fold, compared to SF, as shown in Fig. 13. 
The results of the ELISA experiment show a significant improvement of the 
immune response upon vaccination with p-HASFG. With these experimental 
data, we identified HASFG as a potent immunogen. The DNA vectors used in this 
study might display a synergistic effect in combination with a viral vector, a 
protein or an inactivated virus boost. 
 
Taken together, with this DNA vaccination strategy to combat the SARS-CoV, we 
showed a significantly enhanced immune response in mice, immunized with 
HASFG. The immune response raised by the different recombinant proteins used 
in our study was dependent on (1) the expression level of the protein and (2) the 
sorting to the lipid-enriched microdomains. The sorting of the proteins in this 
study was dependent on the GPI-anchor signal sequence and the retention 
signal of the S protein. Therefore, HASFG displayed the strongest humoral 
immune response, containing the HA-leader for enhanced expression and the 
GPI-anchor for efficient antigen presentation on the cell surface. 
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Besides the humoral immune response, DNA vaccines raise also a cellular 
immune response (Kirman & Seder, 2003, Majumder et al., 2003, Wilson et al., 
2003). However, our investigations did not allow identification of the cellular 
immune response, which might be induced by our vaccination protocol. 
Our findings together with the results of other studies (Chao et al., 1987, Fanning 
et al., 2003, Gething & Sambrook, 1982) raise the question, whether the HA-
leader and the GPI-anchor could be used as a model. We speculate that HA-
tagged and GPI-anchored antigens may induce generally a higher immune 
response than conventional antigens. The exchange of the original leader 
sequence by the HA-leader enhances greatly the expression efficiency. The 
attachment of a GPI-anchor alters the trafficking of a given protein and directs it 
towards DIG’s on the cell surface. This process is dependent on the GPI-anchor 
and not on the sequence of the target antigen. The improved immune response 
of the GPI-anchored S-proteins originated thus in the localization of the protein 
on the cell surface, in the export efficiency, the density of the antigen in a single 
raft domain and in the lateral mobility given by the anchor. These characteristics 
would provide an optimized presentation of the antigen to the immune system. 
We might therefore speculate, that any other given antigen, naturally not co-
localizing with DIG’s, could show an improved immune response upon 
attachment of the HA-leader and linkage to a GPI-anchor. 
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5 OUTLOOK 
Up to date there has been no successful vaccination reported against the SARS-
CoV. Preclinical trials of several studies showed protection upon mice challenge 
with the SARS-CoV, but the following clinical trials were all insufficient in their 
immune response. This should demonstrate the difficulties in vaccination 
development for this virus, taken into account the numerous attempts made in 
the past three years. 
The results showed in this study identified the potential of the HA-tag and the 
GPI-anchor as genetic modifications increasing the humoral immune response. 
These two sequence modifications did not provide the necessary level of 
neutralizing antibodies for protection of mice. However, the potency of this 
vaccination strategy could be enhanced by the synergistic effect of a combination 
treatment. A synergistic effect could improve the humoral and cellular immune 
response. This combination treatment could consist of the DNA vaccine as a 
prime, and a viral vector, a protein or an inactivated virus as a boost. DNA 
priming and protein boosting have been shown to increase antibody responses 
(Coban et al., 2004, Konishi et al., 2003, Letvin et al., 1997). 
Furthermore, the shut-off of the host cell protein synthesis after natural virus 
infection should be considered. This problem could be overcome by sequence 
optimization, which may concern the coding gene sequence, the non-coding 
mRNA leader sequence or the promoter/enhancer sequence. We may speculate 
about further improvement of our S-GPI anchor vaccine after sequence 
optimization. 
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PART II 
 
 
6 INTRODUCTION 
6.1 THE INTERFERON (IFN) SYSTEM 
Interferon’s (IFNs) were discovered as antiviral agents during studies on virus 
interference by Isaacs and Lindenmann in 1957 (Isaacs and Lindenmann, 1957). 
IFNs are a family of cytokines that act early in the innate immune response and 
represent the first line of defense after virus infection. IFNs are classified into two 
subtypes: the type I IFNs, which are also known as viral IFNs and include IFN-β, 
IFN-ω and several IFN-α genes. The type II IFN also known as immune IFN 
comprises a single gene that codes for IFN-γ. Recently, the type III IFNs a novel 
class of cytokines was discovered and named IFN-λ or interleukin (IL) 28/29. 
This new IFN family comprises three members: IFN-λ1, IFN-λ2 and IFN-λ3. The 
type II IFNs bind to a unique receptor. Despite this, they share many functional 
characteristics with IFN-α/β (Ank et al., 2006). The viral IFNs are induced by 
virus infection, whereas the type II IFN is induced by mitogenic or antigenic 
stimuli. Most types of virally infected cells are capable of synthesizing IFN-α/β in 
cell culture. However, plasmacytoid dentritic cells (pDCs) represent the natural 
IFN-α producing cells of the body (Diebold et al., 2003). IFN-α induces IFN-γ 
production in natural killer cells (NK) and T cells and stimulates their cytotoxic 
capacity (Matikainen, 2001)(Samuel, 2001). Furthermore IFN-α activates 
macrophages and stimulates dentritic cell maturation (Veckman, 2006). 
IFNs are indispensable for vertebrates to control viral infections. Mice with a 
targeted deletion in the type I IFN receptor were unresponsive to IFN-α/β and 
succumb to viral infections despite having a normal adaptive immune system 
(Muller et al., 1994, Ryman et al., 2000). The disruption of a single IFN-induced 
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gene may cause complete loss of innate immunity against a particular type of 
virus. Inbred mice with a defect in their IFN-regulated Mx1 gene show an 
increased susceptibility to influenza and influenza-like viruses (Lindenmann, 
1964, Staeheli et al., 1988). Introduction of mouse or human Mx is sufficient to 
reconstitute partially resistance of susceptible mice (Pavlovic et al., 1995). 
Likewise, humans die of viral disease at an early age if they happen to acquire 
genetic defects in the IFN system (Dupuis et al., 2003). 
IFNs can induce the synthesis of more than 400 cellular proteins, called IFN-
stimulated genes (ISGs), including enzymes, signaling proteins, chemokines, 
transcription factors, heat shock proteins, and apoptotic proteins (Der et al., 
1998).  
6.1.1 GENE INDUCTION OF TYPE I IFN 
Two events are required to trigger an effective anti-viral innate immune response: 
(1) the detection of the invading virus by pattern-recognition receptors (PRR) and 
(2) initiation of protein signaling cascades that regulate the synthesis of IFNs. 
Viral infection is sensed by two independent receptor systems that trigger the 
production of type I IFN (Fig. 16). The type I IFNs exhibit a wide breath of 
biological activites: antiviral, antiproliferative, stimulation of cytotoxic activity on a 
variety of cells of the immune system (T cells, NK, monocytes, macrophages, 
and dentritic cells) (Pestka et al., 2004). These receptor systems localize to 
different compartments and recognize different viral particles as ligands. Toll-like 
receptors (TLR) represent one of the receptor systems that induce IFN-α/β as 
well as the newly discovered IFN-λ production (Ank et al., 2006). They are 
associated with the cell membrane in endosomes and and represent therefore 
the extracytoplasmic pathway for pathogen sensing. TLR7/8 are receptors for 
G/U rich single-stranded RNA (Heil et al., 2004) and TLR9 recognizes 
unmethylated CpG DNA present in DNA viruses (Bauer et al., 2001). TLR3 
represents a more general sensor of viral infection through detection of double-
stranded RNA, a by-product of viral replication and transcription for both RNA 
and DNA viruses (Alexopoulou et al., 2001). The TLR pathway induces IFN 
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production through several signaling proteins that ultimately lead to the activation 
of transcription factors ATF-2/c-Jun, NF-κB, IFN regulatory factor 3 (IRF3) and 
IRF7. 
The second receptor system senses dsRNA by RNA helicases localized in the 
cytoplasm. Two such sensors have so far been described: the retinoic acid 
inducible gene I (RIG-I;(Yoneyama et al., 2004) and melanoma differentiation-
associated gene5 (Mda5). RIG-I is essential for the production of IFNs in 
response to RNA viruses including paramyxoviruses, influenza virus and 
Japanese encephalitis virus (JEV), whereas Mda5 is critical for picornavirus 
detection (Kato et al., 2006). RIG-I and Mda5 activate NF-κB and IRFs through 
the recently identified adaptor protein MAVS (mitochondrial anti-viral signaling 
protein; (Andrejeva et al., 2004, Seth et al., 2005). How MAVS is regulated by 
RIG-I/Mda5 and how it activates downstream kinases remains largely unknown. 
The mitochondrial localization of MAVS seems to be essential for its signaling 
function, how mitochondria play a role in activation of kinases remains to be 
investigated. Synthetic dsDNA activates a MAVS dependent pathway, although a 
receptor responsible for DNA recognition has not been identified. Evidence for a 
TLR and RIG-I independent pathway in recognition of cytoplasmic DNA has 
recently been obtained (Ishii et al., 2006, Stetson & Medzhitov, 2006). 
Plasmacytoid DCs (pDCs) mainly use mechanisms for the induction of IFNs that 
do not involve RIG-I (Kato et al., 2006). pDCs are specialized IFN producers and 
represent a major source of IFN-α in humans (Colonna et al., 2002). In pDCs, the 
TLR system appears to play a more important role in the induction of type I IFNs. 
This suggests that pDCs have developed specialized mechanisms for the 
detection of viruses. Moreover it is well known that pDCs are difficult to infect with 
viruses. Therefore, viral recognition in pDCs may mainly depend on endocytosis 
of viral particles rather than direct infection.  
Secreted IFN-α/β interact with a receptor on the cell surface, resulting in the 
activation of the IFN-α/β signaling cascade. This activation ultimately results in 
expression of antiviral active proteins. 
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Figure 16.A: Two independent signaling pathways mediate the IFN-α/β synthesis: (1) 
TLR pathway: endosomal TLR3, 7, 8 and 9 activate IFR3/7, NF-κB and ATF-2/c-Jun. 
(2) dsRNA leads to activation of IRF3 and NF-κB by RIG-I and MAVS (adapted from 
Seth R. et al, Cell Research, 2006); B: Induction of IFN-α/β production in pDCs 
activated by TLR signaling (adapted from Haller O. et al, Virology, 2006). 
6.1.2 IFN-α/β INDUCED SIGNAL TRANSDUCTION 
Secreted IFN-α/β species can interact with the IFN-α/β receptor (IFNAR) on the 
surface of the infected cell or of neighboring cells. IFNAR sends a signal to the 
nucleus through the JAK-STAT pathway, which induces expression of genes with 
antiviral activities. Fig. 17 illustrates the individual steps in the IFN-α signaling 
pathway. 
There are two subunits of the IFN-α/β receptor: IFNAR1 and IFNAR2 (Novick et 
al., 1994). IFNAR1 and IFNAR2 heterodimerise upon stimulation by IFN-α/β. The 
cytoplasmic tails of the two subunits of IFNAR are associated with the JAK 
tyrosine kinases Jak1 and Tyk2. Jak1, when bound to IFNAR2, can 
phosphorylate and activate Tyk2, bound to IFNAR1 (Gauzzi et al., 1996). 
Activated Tyk2 can then cross-phosphorylate Jak1. Activated Jak1 and Tyk2 are 
responsible for the sequential phosphorylation of IFNAR1 and two signal 
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transducer and activator of transcription proteins (STAT): STAT1 and STAT2. 
Phosphorylation of IFNAR1 by Jak1 allows the signal transducer molecule 
STAT2 to bind to the receptor. This results in phosphorylation of STAT2 creating 
a binding site for STAT1. Bound STAT1 is phophorylated and together with 
STAT2 dissociates from the receptor complex as a heterodimer (Leung et al., 
1995). The P-STAT1/P-STAT2 complex interacts with IRF9 (p48) forming the 
IFN-stimulated gene factor (ISGF3) and translocates to the nucleus. ISGF3 
facilitates transcription of IFN-stimulated genes (ISGs) by recognizing and 
binding to a sequence called the IFN-stimulated response element (ISRE). 
 
 
Figure 17: IFN-α/β signaling pathway. IFN-α triggers the IFN-
receptor (IFNAR) and activates the signaling cascade resulting in 
activation of expression of IFN-inducible genes like Mx. 
 
The receptor-activated kinase 1 (RACK1) is playing a pivotal role in this signaling 
mechanism. RACK1 is a scaffold associated with Tyk2 and Jak1 (Usacheva et 
al., 2003), as well as with IFNAR2 and STAT1 (Croze et al., 2000). The 
interaction between IFNAR and STAT1 is not direct, but mediated by RACK1 
(Kubota et al., 2002, Stark et al., 1998). RACK1 is required for recruitment and 
activation of IFN-αinduced STAT1 activation and transduction of IFN-α signaling 
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(Yokota et al., 2003). Unlike the interaction between RACK1 and STAT1, RACK1 
remains associated with the Janus kinases upon phosphorylation (Usacheva et 
al., 2003). 
IFN-α/β mediated activation of ISGF3 leads to transcriptional stimulation of more 
than 100 cellular genes (Der et al., 1998). Among them are the well characterized 
IFN-inducible antiviral enzymes myxovirus resistance protein (Mx), protein kinase 
R (PKR) and 2’5’-oligoadenylate synthetase (OAS). PKR and 2’5’-OAS are not 
only transcriptionally activated by IFN-α/β but also directly by dsRNA (Sarkar & 
Sen, 2004). 
6.1.3 INTERFERON STIMULATED GENES (ISGS) WITH ANTIVIRAL 
ACTIVITY 
6.1.3.1 MX PROTEINS 
Mx proteins are IFN-inducible GTPases that belong to the dynamin superfamily 
of large GTPases (Haller & Kochs, 2002) and display an antiviral activity. They 
were discovered in an inbred mouse strain that showed a high degree of 
resistance towards infection with influenza A virus. Two distinct Mx GTPases are 
expressed in humans, MxA and MxB. MxA is localized in the cytoplasm and 
displays, unlike MxB, antiviral activity. MxA has the ability to associate with viral 
nucleocapsids from different virus families including Orthomyxoviridae, 
Paramyxoviridae, Rhabdoviridae and Bunyaviridae, inhibiting their transport 
and/or biological properties, therefore blocking viral replication (Weber et al., 
2000). Embryonic fibroblasts derived from transgenic mice expressing human 
MxA cDNA showed reduced susceptibility for influenza A and VSV (Pavlovic et 
al., 1995). MxA has no other known functions than the antiviral activity. 
Mx GTPases are not constitutively present in the cells and their expression is not 
directly inducible by viruses or dsRNA (Bazzigher et al., 1992). Mouse and 
human Mx genes contain an ISRE in their upstream regulatory region 
(Horisberger et al., 1990) and are under tight transcriptional control, stimulated 
exclusively by IFN-α/β via the JAK-STAT signaling pathway (Dupuis et al., 2003). 
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Therefore, Mx is considered to be an excellent marker for IFN action in clinical 
settings (Roers et al., 1994). 
After induction, Mx mRNA is rapidly accumulated and reaches highest levels at 
5-10 hours post IFN-α induction and returning to basal levels within 24-48 hours 
post IFN-α induction (Aebi et al., 1989). Mx proteins appear to be very stable in 
cells. Accumulation of Mx proteins reaches its maximum between 24 and 48 
hours post infection. The protein levels stay high for several days, the half-life of 
MxA exceeding 48 hours (Ronni et al., 1993, Ronni et al., 1995). 
6.1.3.2 DS-RNA ACTIVATED PROTEIN KINASE R (PKR) 
PKR is a serine/threonine protein kinase induced by dsRNA-mediated 
autophosphorylation. Activation of PKR results in phosphorylation and 
inactivation of the translation initiation factor eIF-2α (Williams, 1999). As a result, 
protein synthesis is blocked and viral replication inhibited. 
6.1.3.3 2’5’-OLIGOADENYLATE SYNTHETASE (OAS) 
Expression of OAS is strongly induced by IFN-α/β and requires the presence of 
dsRNA for activation (Hovanessian et al., 1977). Activated OAS catalyzes the 
polymerization of ATP into 2’,5’-linked oligoadenylates of various lengths. These 
oligonucleotides bind and activate RNase L, a cellular endonuclease which 
degrades cellular and viral RNA (Malathi et al., 2005) and thus is responsible for 
the inhibition of viral replication (Rebouillat & Hovanessian, 1999). 
6.1.4 VIRAL EVASION 
Despite the fact that high vertebrates have developed an efficient innate and 
adaptive immune system, different viruses represent a continuous threat to 
humans, especially when no preventive measures, such as vaccination, are 
applied. Viruses developed counteracting measures, which allow the virus to 
escape the IFN system of the host organism (Basler et al., 2000, Goodbourn et 
al., 2000). Different virus families are characterized by the presence of specific 
viral IFN antagonists lacking homology with those from other families. 
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Nevertheless, viral IFN antagonists focus on either of the four strategies: (1) Viral 
host shut-off, (2) interference with the IFN induction pathway (IRF3 pathway), 
(3) interference with IFN signaling (JAK-STAT pathway) or (4) interference with 
the IFN effector proteins (PKR pathway) (Weber et al., 2003). 
6.1.4.1 VIRAL HOST CELL SHUT-OFF 
Host shut-off is a virus-mediated inhibition of the cellular machinery at a 
transcriptional level. It has been proposed for some viruses, that the main reason 
of the host shut-off is suppression of the IFN production (Ferran & Lucas-Lenard, 
1997, Lyles, 2000, Stojdl et al., 2003). Inhibition of the innate immune response 
facilitates the infection of the host cell. The production of inducible genes (like 
IFN production) is blocked by the inhibitory effect of the virus on the host gene 
transcription. The housekeeping genes display the decline in mRNA much later in 
infection (Billecocq et al., 2004). This is beneficial to the virus, as viruses depend 
on a functional cellular environment and cannot afford to disturb the entire 
cellular metabolism, risking the loss of the host. 
This general block of transcription in the host cell is a strategy only used by 
viruses with a lytic replication cycle. The mechanisms by which the host cell is 
shut off are very diverse. The NSs protein of the Rift Valley Fever Virus (RVFV) 
impairs proper assembly of the RNA Polymerase II (Le May et al., 2004), 
whereas the influenza A NS1 protein can bind to cellular mRNAs and impair their 
post-transcriptional processing and nuclear export (Chen et al., 1999, Fortes et 
al., 1994, Li et al., 2001). 
6.1.4.2 VIRAL INTERFERENCE WITH THE IFN INDUCTION PATHWAY 
A prominent target to counteract the IFN system is the dsRNA, a characteristic 
by-product of viral replication. Proteins from many unrelated viruses inhibit 
activation of IRF3. They prevent IFN-α/β production by initial phosphorylation of 
IRF3 and subsequently, its dimerization and translocation to the nucleus. 
Examples are the VP35 protein of Ebola virus (Basler et al., 2003), and the 
NS1/NS2 complex of respiratory syncytial virus (RSV) (Bossert et al., 2003). 
Simian Virus 5 (SV5) V protein also inhibits activation of IRF3 (He et al., 2002, 
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Poole et al., 2002). Influenza and poxviruses encode dsRNA binding proteins 
NS1 and E3L that prevent IRF3 activation (Garcia-Sastre et al., 1998b, Talon et 
al., 2000, Wang et al., 2000), at least in part by sequestering dsRNA and 
preventing stimulation of cellular sensors of dsRNA, such as RIG-I and Mda5 
(Garcia-Sastre & Biron, 2006). Hepatitis C virus blocks the TLR3 and RIG-I 
mediated activation of IFN by cleavage of MAVS and TRIF by the viral NS3/4A 
protease (Meylan et al., 2005). 
6.1.4.3 INHIBITION OF IFN-α/β SIGNALING 
Many viruses suppress the specific IFN signaling pathway to prevent ISG 
expression (Fig. 18). Poxviruses secrete a soluble form of the IFNAR that 
sequesters type I IFN before it can bind to the natural IFNAR (Symons et al., 
1995). The V protein of SV5 and Mumps viruses (MuV) inhibits the JAK-STAT 
pathway by inducing the degradation of STAT1 (Didcock et al., 1999b). MuV V 
promotes disruption of the IFN receptor RACK1 interaction by binding to RACK1 
with a high affinity, resulting in the subsequent release of STAT1 from IFNAR 
(Kubota et al., 2002). The measles virus (MeV) shows suppression of Jak1 
phosphorylation induced by IFN-α. RACK1 was found to act as interaction 
partners of two viral proteins: MeV and MeC. 
The scaffold protein RACK1 can associate with various viral proteins, including 
adenovirus E1A protein (Sang et al., 2001), Epstein-Barr virus BZLF1 protein 
(Baumann et al., 2000), human immunodeficiency virus-1 Nef protein (Gallina et 
al., 2001), and influenza A virus M1 protein (Reinhardt & Wolff, 2000). In the 
latter, RACK1 acts as a scaffold for the phosphorylation of influenza A M1 by 
PKC (Reinhardt & Wolff, 2000). 
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Figure 18: Viral interference in the IFN-α/β signaling pathway. Degradation of STAT1 by 
SV5 V protein; Inhibition of phosphorylation of Jak1 and Tyk2 by measles virus V- and C-
protein and binding of the adenoviral E1A protein and sequestration of the ISGF3 complex. 
 
6.1.4.4 INHIBITION OF IFN EFFECTOR PROTEINS 
An efficient way to escape the IFN response is to directly inhibit the IFN effector 
proteins. All viruses with the capacity to sequester dsRNA are able to prevent 
activation of PKR or the 2’5’-OAS/RNase L system (Bergmann et al., 2000). The 
influenza NS1 protein inhibits activation of 2’5’-OAS by sequestering dsRNA 
away from the antiviral enzyme (Min & Krug, 2006). Furthermore influenza NS1 
inhibits two cellular proteins that are required for the 3’-end processing of cellular 
pre-mRNAs: the cleavage and polyadenylation specificity factor (CPSF) and 
poly(A)-binding protein II (PABII) (Chen et al., 1999, Nemeroff et al., 1998). 
Herpesvirus, a complex DNA virus expresses an inhibitor of the PKR antiviral 
pathway, the ICP34.5 protein. ICP34.5 recruits a cellular phosphatase to 
dephosphorylate eIF-2α, and thus release the translational block by PKR (He et 
al., 1997). Moreover herpes simplex virus is able to generate 2’-5’-oligoadenylate 
derivatives that bind to and inhibit RNase L and thus prevent degradation of RNA 
(Cayley et al., 1984). 
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6.2 INFLUENZA A VIRUS 
Influenza viruses are negative stranded, segmented, enveloped RNA viruses 
containing helical ribonucleocapsid (viral ribonucleoprotein; vRNP) and belong to 
the Orthomyxoviridae family (Lamb & Takeda, 2001). Virus particles are 
approximately 100nm in diameter and of spherical shape (Fujiyoshi et al., 1994). 
The genome of this virus comprises eight negative-stranded RNA segments, 
which direct the synthesis of 11 viral proteins in infected cells, as shown in Table 
4. Four of these proteins, the nucleoprotein (NP), which encapsidates the viral 
RNA, and the three subunits of the polymerase (PB1, PB2 and PA) are 
associated with each of the viral genomic RNAs forming vRNPs. Three of the 
proteins: hemagglutinin (HA), neuraminidase (NA), and the ion channel (M2), are 
transmembrane proteins, and the two structural components, the matrix (M1) and 
nuclear export protein (NEP), are internal components of the viral particle. NS1 
and the recently discovered facilitator of apoptosis PB1-F2 are besides the 
polymerase polyprotein the only non-structural proteins encoded by the viral 
genome (Lamb et al., 1985, O'Neill et al., 1998). 
 
 
Table 4: Genome of the Influenza virus. 11 viral genes are divided into 8 RNA segments, 
encoding for the proteins described. 
 
The emergence of new influenza strains in the human population occurs via 
transmission from animal species, most notably birds. Transmission to humans is 
most commonly thought to occur through an intermediate such as swine 
(Webster et al., 1992). Typically, human and avian influenza viruses are quite 
different and are not cross-infectious. However, pigs can become infected with 
both types of viruses, and it has been proposed that they act as a ‘mixing vessel’ 
Segment Size(nt) Protein Function
1 2341 PB2 Transcriptase (Polymerase): cap binding
2 2341 PB1 Transcriptase (Polymerase): elongation
3 2233 PA Transcriptase: protease activity (?)
4 1778 HA Haemagglutinin: receptor binding; fusion activity
5 1565 NP Nucleoprotein: binds RNA; part of transcriptase complex; nuclear/cytoplasmic transport of vRNA.
6 1413 NA Neuraminidase: release of virus.
7 1027 M1 Matrix protein: major structural component of virion.
M2 Integral membrane protein - ion channel (H+).
8 890 NS1 Non-structural protein 1: effects on cellular RNA transport, splicing, translation; anti-IFN protein.
NEP Nuclear export protein: nucleus+cytoplasm; active in mRNA export from nucleus.
PB1-F2 Facilitator of apoptosis: protein inducing cellular apoptosis.
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for the transmission of avian influenza viruses to humans. Occasionally, direct 
avian-human transmission can occur, as demonstrated in the case of the recent 
H5N1 virus. 
6.2.1 INFLUENZA VIRUS LIFE CYLCE 
Influenza virus particles bind to cell surface sialic acid, ubiquitously present on 
glycoproteins or glycolipids. The specificity of the sialic acid (avian: α2,3-linked 
sialic acid or human: α2,6-linked sialic acid) and preferred binding of a particular 
strain of influenza virus to a specific sialic acid receptor are important 
determinants for species-specific restriction of influenza viruses (Matrosovich & 
Klenk, 2003).  
Influenza viruses infect cells via multiple endocytic pathways, with both calthrin-
mediated and clathrin- and caveolin-independent pathway(s). Both pathways 
lead to viral fusion with similar efficiency (Lakadamyali et al., 2004, Sieczkarski & 
Whittaker, 2002). Viruses taking the clathrin-mediated pathway enter cells via the 
de novo formation of clathrin-coated pits at viral binding sites, a process that is 
dependent on dynamin, a cellular GTPase (GTP phosphohydrolase; (Roy et al., 
2000). After internalization, the viruses are trafficked via early endosomes to late 
endosomes, where the acid pH~5.0 generated in these organelles by the 
vacuolar proton ATPase, induces a conformational change in the viral HA. This 
conformational change triggers viral fusion with the endosome and leads to the 
release of the viral genome (Hernandez et al., 1996, Skehel & Wiley, 2000). In 
the acidic pH of the endosome, the cleaved HA undergoes conformational 
changes causing fusion of viral and endosomal membranes (Colman & 
Lawrence, 2003). Virus particles containing uncleaved HA can bind and be 
endocytosed but cannot undergo fusion and are therefore non-infectious. The ion 
channel M2 opens up in the acidic pH of the endosome, acidifies the internal 
virion core, and thereby enables the release of vRNP from M1 into the cell 
cytoplasm. vRNPs are then imported into the nucleus through nuclear pores 
using nuclear transport signals of NP (Neumann et al., 2000). 
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Influenza viruses are one of a few RNA viruses to undergo replication and 
transcription in the nucleus of their host cell (Whittaker & Helenius, 1998). In the 
nucleus, the vRNPs serve as templates for the production of two forms of 
positive-sense RNA: viral messenger RNA (mRNA) and complementary RNA 
(cRNA; Krug et al., influenza viruses, Plenum Press, New York, USA, 1989). The 
synthesis of mRNA is catalyzed by the viral RNA-dependent RNA polymerase 
(comprising the three subunits PA, PB1 and PB2), which is part of the incoming 
vRNP complex. Viral mRNAs are processed in an analogous fashion to 
eukaryotic mRNAs. They are capped (contain a methylated 5’-guanosine 
residue) by a process called cap-snatching and polyadenylated (contain a 
sequence of polyadenylic acid at their 3’-end), and are exported from the nucleus 
for translation by cytoplasmic ribosomes. In the cap-snatching process, cellular, 
nuclear RNA fragments are cleaved at their 5’ ends by a virus-encoded, cap-
dependent endonuclease that is part of the RNA polymerase. The resulting 10- to 
13-nucleotide-long capped fragments serve as primers for the initiation of viral 
mRNA synthesis (Plotch et al., 1981). The viral cRNA is neither capped nor 
polyadenylated, and remains in the nucleus, where it serves as a template for the 
production of negative-sense genomic RNA (viral RNA; vRNA). The nuclear 
export of viral mRNA utilizes the ‘translocation machinery’ of the host cell and is 
controlled by NS1 (Chen & Krug, 2000). Many viral proteins (NP, M1, NEP and 
the polymerases) are imported into the nucleus upon synthesis for the final 
stages of replication and for vRNP assembly. 
vRNPs containing minus-strand vRNA, NP, the three polymerase proteins and 
NEP are transported out of the nucleus through the chromosome region 
maintenance 1 (CRM1) protein together with M1 (Neumann et al., 2000). How 
M1 and vRNP, individually or jointly are transported to the budding site remains 
unclear. Cytoskeletal components, particularly microfilaments, interact with the 
NP of the vRNP and the M1 complex and thereby may facilitate the transport of 
these components to the assembly site (Avalos et al., 1997). 
M1 is central to the assembly. M1 proteins bind to vRNPs and the plasma 
membrane to form a shell beneath the virus envelope (Nayak et al., 2004). The 
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structural organization of M1 in the virion and its involvement in multiple 
interactions with other viral proteins and RNP support the assumption that 
budding of negative-strand RNA viruses is orchestrated by this protein (Garoff et 
al., 1998). 
For the final budding step, it has recently been shown that the viral components 
come together at the detergent-insoluble glycolipid-enriched domains (DIGs), or 
lipid rafts (Scheiffele et al., 1999, Zhang & Lamb, 1996). The final release of 
viruses from the cell surface relies on the action of the viral NA. NA (sialidase) 
acts as a receptor-destroying enzyme, by removing sialic acid (the viral receptor) 
from the surface of host cells (Colman & Lawrence, 2003). Without this step, the 
newly assembled virus particles would immediately re-bind to their receptor and 
not be released into the extra-cellular space. Instead, they would remain attached 
to the cell in large clumps. NA is therefore important for the efficient release of 
viruses. The establishment of a productive infection is dependent on both NA and 
HA. 
6.2.2 INFLUENZA MATRIX PROTEIN M1 
M1 is the most abundant protein (3000 molecules/virion) in the virus particle and 
a major structural component of the virion. M1 has multiple regulatory functions 
during the infectious cycle, which include the dissociation of M1 from RNP from 
the viral shell to enable transcription. This step is required for the release of viral 
RNP into the cytoplasm of the infected host cell. Dissociation is triggered by 
transport of H+ ions across the viral membrane by M2 (Bui et al., 1996, Helenius, 
1992, Martin & Helenius, 1991). Furthermore, M1 mediates inhibition of viral 
transcription (Hankins et al., 1990, Perez & Donis, 1998, Watanabe et al., 1996, 
Ye et al., 1989). It also has been shown that M1 is transported during early viral 
replication from the cytoplasm into the nucleus, via a nuclear localization signal 
(NLS) (Ye et al., 1989), where M1 associates with newly synthesized RNPs (Bui 
et al., 1996, Rey & Nayak, 1992). The transport of RNP from the nucleus to the 
cytoplasm requires the binding of M1 to RNP, which also prevents RNP from 
reentering the nucleus (Huang et al., 2001, Martin & Helenius, 1991). 
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It has been shown that M1 is the major virus assembly organizer and the major 
driving force in the budding process (Gomez-Puertas et al., 2000). Interactions of 
M1 with HA, NA, M2, NEP and host cell lipid membranes occur on the 
cytoplasmic side of the membrane as part of the process of virion maturation and 
budding at the cell surface (Enami & Enami, 1996, Lamb et al., 1985, Ruigrok et 
al., 2000, Yasuda et al., 1993, Zhang & Lamb, 1996). 
M1 becomes phosphorylated during influenza virus infection. Protein kinase C 
(PKC) is proposed to be the M1-phosphorylating enzyme, whereas the receptor 
activated kinase C1 (RACK1) is thought to be the scaffold for this 
phosphorylation (Reinhardt & Wolff, 2000). The phosphorylation status is thought 
to determine the different regulatory roles of M1. To date there is no information 
about the different regulatory functions of M1 in its different activated states. 
6.3 AIM OF THIS PROJECT 
The basis of this project is the observation of the down-regulation of MxA of M1-
transfected A549 cells by immunofluorescence. This led to the hypothesis, that 
influenza A may have the ability to counteract the innate immune response by 
M1, an alternative mechanism to NS1. The aim of this study was to identify the 
M1-protein as an antagonist of the IFN-α signaling pathway and to identify the 
interaction partners of M1 in the signaling cascade. 
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7 MATERIALS AND METHODS 
7.1 CELL CULTURE AND TRANSFECTION 
Human embryonal kidney cells (HEK293), human lung carcinoma cells (A549) 
and African green monkey kidney cells (Vero E6) were cultured at 37°C and 5% 
CO2 in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) containing 10% fetal 
calf serum (FCS). The cells were split every second day before reaching 
confluency. 
A549 cells were transfected with LipofectamineTM 2000 as described in chapter 
3. 
7.2 VIRUS INFECTION WITH INFLUENZA A/WSN/33 
Influenza A/WSN/33 virus (WSN) is a mouse adapted H1N1 human strain. A549 
and Vero E6 cells were splitted 10-12h previous to the infection. Cells displayed 
about 95% confluency at the time of infection. Cells were infected with 10 
multiplicities of infection (MOI). The virus stock had a titer of 3.16x108 TCID/ml, 
equaling 3.16x108 TCID/ml / 1.44 = 2.195x108 virus/ml. The culture medium was 
exchanged (DMEM, 2%FCS, 20mM Hepes) at time of infection. For exogenous 
IFN-α stimulation upon infection 1000 U/ml Roferon (Roche) was applied to the 
cells in fresh DMEM medium. Cells were harvested 6-48h post infection, 
depending on the experiment, and protein expression and cell viability were 
analyzed. 
7.3 DUAL-LUCIFERASE® REPORTER ASSAY 
Luciferase reporter assays were performed in 12 well plates with infected or 
transfected HEK293 or Vero cells. Assays were performed with the dual-
Luciferase® reporter system kit (Promega) according to the manufacturer’s 
instructions: Cells co-transfected with 0.6µg/well p(9-27)4tkD(-39)lucter (a 
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plasmid encoding the firefly luciferase (FFL) under the control of an ISRE) and 
0.04µg/well pRL-TK (a plasmid encoding the renilla reniformis Luciferase, 
expressed constitutively under the control of the HSV tyrosine kinase promoter) 
as an internal control were rinsed with PBS and then incubated for 15min in an 
appropriate amount of passive lysis buffer (PLB, for a 12 well plate 250µl). 10µl 
of cell lysate were added to 50µl of LARII. Luminescence of FFL was measured 
in a Sirius Luminometer (Berthold detection systems). 50µl of Stop&Glo reagent 
were added and the luminescence of RRL was measured. 
 
A: 
 
 
B: 
 
Fig. 19.A and B: Time scale of how cells were treated before the luciferase reporter assay 
was performed. A: cells were transfected with M1, SV5 V or RFP, and the luciferase 
constructs, stimulated with IFN-α 24h later and extracted another 12h (36h post transfection) 
for a luciferase reporter assay. B: cells were transfected with the luciferase constructs and 
infected with influenza A/WSN/33 12h later. 2h p.i. the cells were stimulated with IFN-α and 
another 10h later cells were extracted for a luciferase reporter assay. 
7.4 PROTEIN EXTRACTION 
A549 cells were washed twice in ice cold phosphate-buffered saline (PBS, Gibco) 
and cells were lysed in Ripa buffer (20mM Tris-HCl, 135mM NaCl, 2mM EDTA, 
1% Triton X-100, 0.1% SDS, 0,5% Deoxycholat, 10% glycerol and protease 
inhibitors) for 10min on ice. The cells were then scraped from the dish and 
transferred into an eppendorf tube. The lysate was centrifuged at 13000rpm and 
4°C for 5min. Protein concentration was measured by BCA (Micro BCA protein 
assay reagent kit; Pierce). 
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7.5 ANTIBODIES AND WESTERN BLOTTING 
For Western blotting, infected cells were diluted in SDS Laemmli buffer and 
boiled at 95°C for 10min. Samples were electrophoresed by SDS-PAGE, and the 
proteins were transferred onto nitrocellulose membranes (HybondTM-ECLTM). 
Membranes were blocked with 5% skim milk TBS-T buffer (20mM Tris-HCl 
pH7.5, 0.5 M NaCl, 0.05% Tween 20) and rabbit anti-STAT1, rabbit anti-
phospho-STAT1, rabbit anti-phospho-STAT2, rabbit anti-phospho-Tyk2 and 
rabbit anti-phospho-Jak1 (Cell Signaling) antibodies as well as the anti-cortactin 
(Santa Cruz) antibody were diluted 1:1000 in 5% skim milk TBS/Tween buffer. 
Membranes were incubated for 1h at RT or at 4°C overnight, subsequently 
washed 4 times 5min in TBS-Tween and incubated with horseradish peroxidase-
conjugated donkey anti-rabbit (Amersham Biosciences) antibody as secondary 
antibody for 1h at RT. Chemiluminescence detection was performed according to 
the manufacturer’s protocol (ECL detection kit, Amersham Biosciences) after 
washing the membranes 4 times with milk TBS-T buffer for 5min and 2 times with 
TBS-buffer for 5min. 
7.6 CO-IMMUNOPRECIPITATION 
30 µl total volume of protein L-agarose (Santa Cruz) or protein A-agarose 
(Sigma-Aldrich), were washed for each lysate three times with the extraction 
buffer (with protease inhibitors). 2 µg antibody was added to the beads (1:1 
diluted in extraction buffer) and incubated on a turning row at 4°C for 1-3h. The 
bead-AB mix was washed three times with extraction buffer to get rid of soluble 
AB, which would compete with the bead-AB mix for the proteins. Unspecific AB-
binding sites were blocked with 0.5% BSA (10% BSA in PBS stock solution; 
1.5µl/30µl bead-AB volume) for 30min-1h at 4°C. The blocked bead-AB mix was 
washed 3 times with extraction buffer and extracted proteins were added and 
incubated for 1-2h at 4°C. The remaining proteins were selected by washing the 
beads 2 times with extraction buffer with protease inhibitors. Finally the beads 
are centrifuged at 2500rpm for 1min, the supernatant is discarded and the beads 
 65
are boiled in SDS-loading buffer for 10min at 95°C and analyzed by Western 
blotting. 
7.7 STATISTICS 
Numerical data were analyzed for statistical significance using the Student t test 
with tail = 2 and type = paired (1). 
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8 RESULTS 
8.1 INHIBITORY EFFECT OF INFLUENZA A ON THE IFN-
α/β SIGNALING 
8.1.1 INFLUENZA INFECTION DECREASES THE RESPONSIVENESS OF 
ISRE IN A REPORTER ASSAY 
The effect of influenza A on the IFN-α/β signaling cascade was measured 
indirectly using a transient co-transfection method including p(9-27)4tkD(-
39)lucter that expresses the firefly luciferase (FFL) under the control of an ISRE 
(King & Goodbourn, 1998). As an additional control a second plasmid pRL-TK 
encoding the renilla reniformis luciferase (RRL) was expressed constitutively 
under the control of the HSV tyrosine kinase promoter. These constructs have 
been tested by co-transfection in HEK293 cells and stimulation with exogenous 
IFN-α. The expression level of FFL depended linearly on the level of IFN-α 
added to the cells and the activity of the IFN-α/β signaling pathway. 
In order to determine the effect of influenza on the production of FFL and RRL, 
HEK293 cells and Vero cells were infected with influenza. The experimental 
design of the co-transfection and infection experiment is summarized in Fig. 19A. 
Dividing the activity of RRL normalized the activity of FFL. As shown in Fig. 19B 
the IFN-α dependent FFL activity was decreased by 80% in influenza-infected 
HEK293 cells, compared to non-infected cells. This result indicated that influenza 
A reduced the responsiveness of the ISRE-promoter and therefore decreased 
FFL activity. Lysates of infected, non-stimulated cells showed limited increase in 
FFL activity, compared to lysates of non-infected cells. This finding indicated that 
(1) the IFN-α treatment stimulated the ISRE-regulated FFL activity, (2) influenza 
activated the IFN-α signaling pathway in the absence of exogenous IFN-α and 
(3) influenza effectively blocked the activation of the IFN-α signaling upon 
exogenous IFN-α stimulation. The mechanism of induction by influenza virus 
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infection is known to be mediated by the interaction of dsRNA and TLR3, leading 
to the production of IFN-α/β (Alexopoulou et al., 2001, Matsumoto et al., 2004). 
The same experiment was performed with Vero cells, lacking the IFN-α genes. 
As shown in Fig. 19C, FFL activity was equal in non-stimulated, infected and 
non-infected Vero cells, as IFN-α could not be induced endogenously as for 
infected HEK293 cells. A decrease in FFL activity of more than 50% was 
detected in infected, IFN-α stimulated Vero cells, compared to non-infected, IFN-
α stimulated cells. The difference in IFN-α dependent FFL activity in influenza-
infected HEK293 and Vero cells was due to a different efficiency in infectivity of 
the two cell lines. 
 
A: 
 
B: 
 
C: 
 
Figure 19: Inhibitory effect of influenza A on the IFN-α signaling pathway in HEK293 cells (B) 
or Vero cells (C). A: time line of experimental set up. Cells were transfected with a plasmid 
coding for the FFL and another plasmid encoding the RRL 12h ahead of influenza infection. 
The FFL was under control of an ISRE, whereas the RRL was ubiquitously expressed. 
Influenza-infected cells were stimulated with IFN-α 2h p.i. and luciferase activity was measured 
12h p.i. Graphs show the values of 3 independent experiments. p values: p>0.009; p>0.0004; 
p>0.005. 
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8.2 INHIBITORY EFFECT OF INFLUENZA M1 ON THE IFN-
α/β SIGNALING 
8.2.1 OVEREXPRESSION OF M1 DECREASES THE RESPONSIVENESS OF 
ISRE IN A REPORTER ASSAY 
In order to define the viral protein responsible for the inhibitory activity of the 
influenza virus, a transient co-transfection method was used to measure FFL 
activity upon transfection with the M1-protein. The M1-protein was expressed 
under the control of the CMV gene promoter by the plasmid pVR1012-M1. FFL 
and RRL were co-expressed by the plasmids introduced in the experiment 
above. In order to determine the effect of the M1-protein on the production of the 
FFL, the impact of pVR1012-M1 was compared to the empty vector pVR1012. 
HEK293 cells were transfected and 24h later exogenously stimulated with IFN-α. 
Cell lysates were collected 12h post stimulation (Fig. 20A). As depicted in Fig. 
20B, in IFN-α stimulated cells, the FFL activity was inhibited by 60% in pVR1012-
M1 transfected cells. The inhibition of FFL activity in stimulated cells did not show 
a significant difference in cells transfected with 0.6µg pVR1012-M1 than in cells 
transfected with 0.3µg pVR1012-M1 (compare gray bar with brown bar). 
The difference of the FFL activity for the non-stimulated cells transfected with 
either pVR1012 or pVR1012-M1 was not significant. (p>0.223). The inhibitory 
effect of the M1-protein on the IFN-α signaling, compared to pVR1012 appeared 
to be dependent on exogenous IFN-α. 
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B:  
 
Figure 20: A: Time line to show the experimental set up for the reporter assay. B: 
Overexpression of M1 decreases the responsiveness of ISRE in a reporter assay. HEK293 cells 
were co-transfected with pVR1012, pVR1012 and pVR1012M1, or pVR1012M1 and the 
plasmids encoding FFL and RRL. Cells were stimulated with IFN-α and luciferase activity was 
measured. p values: p>0.223; p>0.005. 
 
8.2.2 OVEREXPRESSION OF M1 DECREASES THE RESPONSIVENESS OF 
ISRE IN A REPORTER ASSAY SIMILAR TO THE SV5 V-PROTEIN 
In order to prove the specificity of the inhibitory activity of the M1-protein, the 
effect of over-expressed M1 was compared to two control proteins: red 
fluorescent protein (RFP) and simian virus 5 (SV5) V-protein. The experimental 
set up was the same as in Fig. 20A. Cells were transfected and a saturating 
amount of IFN-α was added 24h post transfection. Cells were harvesed 12h post 
stimulation. 
RFP was expressed under the control of a CMV promoter of the expression 
plasmid pDsRed1-C2 and was not expected to have any effect on the IFN-α 
signaling cascade. The SV5 V-protein was shown previously to be a strong IFN-α 
signaling inhibitor (Didcock et al., 1999a, Didcock et al., 1999b) and served as 
positive control. As shown in Fig. 21, M1 inhibited the FFL activity by 80% 
compared to the RFP indicating a specific inhibition of the IFN-α/β signaling 
pathway by the M1-protein. Similar to the M1-protein, the SV5 V-protein inhibited 
the IFN-α/β signaling pathway also by 80%. Thus, the V-protein and the M1-
protein were shown to affect the IFN-α/β signaling equally well. Since the V-
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protein is known to be a potent inhibitor of the type I IFN signaling pathway, we 
concluded that M1 could be a strong and specific inhibitor of the type I IFN 
signaling pathway. 
Non-stimulated Vero cells showed a statistically significant difference in the FFL 
activity between RFP and the M1-protein (p>0.0004) as well as between the V-
protein and the M1-protein (p>0.00035). The M1-protein showed a weak IFN-α 
independent inhibition of the FFL activity, compared to the IFN-α stimulated cells. 
This observation may be explained by a toxic effect of the plasmid backbone 
containing CpG-rich sequences, which could lead to non-specific activation of the 
IFN-α/β pathway. This finding was confirmed by the result of the non-stimulated 
cells in Fig. 20B. The FFL activity did not show a significant difference in cells 
transfected with pVR1012-M1 or pVR1012, possibly due to the identical 
backbone of the two plasmids. The IFN-α independent effect of the plasmid 
backbone on the activity of FFL was not observed in lysates of IFN-α treated 
cells. The effect might be overruled by the excess amount of IFN-α added. 
 
 
Figure 21: Overexpression of M1 decreases the responsiveness of 
ISRE in a reporter system, similar to the SV5 V-protein. Vero cells were 
co-transfected with pDsRed2-C1 encoding RFP, pEF-SV5-V encoding 
the V-protein, pVR1012-M1 encoding the M1-protein and the plasmids 
encoding the FFL and RRL. Cells were stimulated with IFN-α and 
luciferase activity was measured. 
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8.3 INFLUENZA A INHIBITS MXA 
In order to independently confirm the effects of influenza on the type I IFN 
signaling pathway, MxA protein levels were measured in infected A549 cells. It 
has been shown previously that the MxA production is tightly regulated by a type 
I IFN-stimulated response element (ISRE). As depicted in Figure 22A, the MxA 
expression increased from 6h to 24h after IFN-α stimulation. The time frame from 
18h to 24h was chosen to identify the effect of influenza A on the MxA 
production. Fig. 22B shows the experimental set up of the MxA detection 
experiment. A549 cells were infected and IFN-α stimulated 2, 4 or 6h p.i. 
Stimulated cells were harvested 18h post stimulation and non-stimulated cells 
were harvested 20, 22 or 24h p.i. 
Analysis of non-infected A549 cells (Fig. 22C; lane1) did not show any MxA, 
confirming data (Haller & Kochs, 2002) that MxA expression in absence of IFN-α 
pathway activators is minimal. Analysis of infected cells revealed, that MxA was 
induced upon infection, but remained at a very low level. Comparing lane2 to 
lane4, the level of MxA protein was shown to decrease with time p.i.. MxA is 
known to be stable for several days (Aebi et al., 1989). The observed decrease of 
the MxA protein level cannot be explained by general protein instability, 
suggesting that MxA is degraded upon influenza A infection. 
Fig. 22C showed A549 cells infected with influenza A and stimulated with IFN-α 
2, 4 or 6h p.i. MxA was highly induced by IFN-α stimulation in non-infected cells. 
Interestingly, infection and IFN-α stimulation together showed a strong inhibition 
of MxA expression (lane2). The level of MxA transcripts was shown to be lower, 
the later infected cells were stimulated with IFN-α (lane2-4). 
 
A: 
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Figure 22: Influenza A inhibits the protein expression of MxA. Influenza-infected and IFN-α 
stimulated A549 cells were analyzed by Western blotting. A: Cells were stimulated with IFN-α 
and examined for MxA expression from 0-24h post stimulation. B: time line indicating the 
infection and stimulation treatments for the MxA detection in Fig. 23C and 23D. C: Proteins of 
influenza-infected cells were analyzed 20, 22 or 24h p.i. C: Proteins of influenza-infected and 
IFN-α stimulated 2, 4 or 6h p.i. cells were analyzed 18h post stimulation, resulting in the same 
infection time as B. 
 
8.3.1 INFLUENZA INFECTION OR OVEREXPRESSION OF M1 INHIBIT THE 
EXPRESSION OF MXA 
The Western blot analysis was confirmed by an immunofluorescence experiment, 
detecting the IFN-α induced expression of MxA in influenza-infected A549 cells 
(Fig. 23A). Influenza-infected cells showed an inhibited expression of MxA 
compared to non-infected cells. Furthermore, the immunofluorescence 
experiment of A549 cells overexpressing M1 revealed a suppressed MxA 
expression (Fig. 23B). MxA was equally expressed in A549 cells overexpressing 
GFP. Therefore, M1 was repeatedly shown to be responsible for the interference 
with the IFN-α signaling pathway. 
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Fig.23: IFN-α dependent inhibition of MxA expression. A: Inhibition of MxA expression upon 
influenza infection of IFN-α stimulated A549 cells. B: Inhibition of MxA expression upon 
overexpression of M1 in IFN-α stimulated A549 cells. MxA was equally expressed in A549 cells 
overexpressing GFP. Sections of cells were observed with a confocal microscope equipped with 
a x63 magnification, 2.3 numerical aperture oil immersion lens. 
 
8.4 INHIBITION OF STAT1 PHOSPHORYLATION BY 
INFLUENZA A 
8.4.1 INFLUENZA A DID NOT AFFECT THE STABILITY OF IFN-α/β 
SIGNALING PROTEINS AT EARLY STAGES AFTER INFECTION 
In order to examine the expression of IFN-α signaling proteins upon influenza-
infection, a time course analysis was performed. A549 cells were infected, 
proteins were extracted up to 18h p.i., and analyzed by Western blotting. Total 
cell lysates of A549 cells were harvested and protein levels of STAT1, STAT2, 
Jak1 and Tyk2 were determined. These proteins have been shown to play an 
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essential role in viral interference with the IFN-α signaling by other viruses and 
represent potential targets for influenza A.  
To test whether the virus affects the stability of the signaling proteins we 
determined the total protein amount. As shown in Fig. 24, the level of signaling 
proteins remained constant up to 15h p.i. At 18h p.i., a weak decrease in the 
STAT2 protein level was observed. In order to exclude the effect of virally 
induced protein degradation and apoptosis, an infection time of 12h was chosen 
for all further experiments. 
 
 
Figure 24: Stability of the IFN signaling proteins upon 
influenza infection. A549 cells were infected and harvested at 
the indicated time points and total proteins were extracted. 
Lysates were subjected to Western blot analysis and 
examined for total amounts of STAT1, STAT2, Jak1 and Tyk2. 
 
8.4.2 INFLUENZA A LEADS TO THE INHIBITION OF P-STAT1, BUT DOES 
NOT AFFECT THE PROTEIN LEVEL OF STAT1 
To examine whether the influenza M1-protein antagonizes the IFN-α signaling by 
interfering with the phosphorylation and subsequent activation of STAT1, we 
performed a Western blot analysis with influenza infected, IFN-α stimulated A549 
cells. In a first experiment, the maximal phosphorylation of STAT1 was 
determined between 15 to 30min after IFN-α stimulation (Fig. 25A). 
As shown in Fig. 25B, IFN-α induced phosphorylation of STAT1 in influenza A 
infected cells (lane4) was dramatically suppressed at 20min treatment compared 
to the uninfected control cells (lane3). The protein level of total STAT1 remained 
equal for all cell lysates. STAT1 was not degraded in influenza A infected A549 
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cells. Concluding, IFN-α dependent STAT1 phosphorylation was inhibited by 
infection with influenza A. 
Interestingly, longer exposure of the membranes of Fig. 25B (30min versus 
1min), showed IFN-α independent P-STAT1 in influenza-infected A549 cells. 
This effect was explained by the induction of the type I IFN pathway mediated by 
the interaction of dsRNA with TLR3 (Alexopoulou et al., 2001, Matsumoto et al., 
2004). The IFN-α/β signaling cascade was suggested to be induced by extra 
cellular dsRNA or virus particles sensed at the cell surface, before viral infection. 
Upon infection, the M1-protein was thought to act as IFN-α/β signaling 
antagonist, inhibiting the antiviral activity. 
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Figure 25: IFN-α dependent inhibition of P-STAT1 upon infection with influenza. A549 cells 
were harvested and lysates of extracted proteins were subjected to Western blot analysis 
and examined for STAT1 and P-STAT1. A: Determination of the time frame of maximal P-
STAT1 upon IFN-α stimulation. B: Inhibition of P-STAT1 upon influenza infection and IFN-α 
stimulation (lane3 & 4; 1min exposure) and induction of IFN-α signaling upon influenza 
infection (lane 1 & 2; 30min exposure). A549 cells were stimulated with IFN-α for 20min 12h 
p.i. 
 
8.4.3 OVEREXPRESSION OF M1 LEADS TO THE INHIBITION OF NUCLEAR 
TRANSLOCATION OF STAT1 
Inhibition of STAT1 phosphorylation impairs its transport into the nucleus, as 
heterodimers with P-STAT2 are not built and thus not translocated into the 
nucleus. In order to confirm this hypothesis, an immunofluorescence experiment 
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was performed with A549 cells overexpressing M1. Cells were stimulated with 
IFN-α and M1 and STAT1 were detected. Fig. 26A showed IFN-α dependent 
nuclear translocation of STAT1 in M1-negative A549 cells, whereas cells 
expressing M1 showed no STAT1-translocation into the nucleus. Cells 
overexpressing GFP were not impaired in nuclear translocation of STAT1, as 
depicted in Fig. 26B. This result showed that the STAT1 translocation into the 
nucleus was inhibited by M1 and supports the finding of the Western blot analysis 
displaying a decreased protein amount of P-STAT1. 
 
A: 
 
B: 
Fig. 26: A: IFN-α dependent inhibition of STAT1 translocation into the nucleus in A549 cells 
overexpressing the M1-protein. B: Overexpression of GFP did not impair the nuclear 
translocation of STAT1. Sections of cells were observed with a confocal microscope equipped 
with a x63 magnification, 2.3 numerical aperture oil immersion lens. 
 
8.5 INHIBITION OF TYK2 PHOSPHORYLATION BY 
INFLUENZA A 
In order to further explore the molecular mechanism by which influenza A 
suppressed the type I IFN signaling pathway, the proteins upstream of STAT1 in 
the signaling were investigated. Tyk2 is located upstream of STAT1 in the IFN-
α/β signaling and is directly responsible for the STAT1 phosphorylation (Leung et 
al., 1995). Therefore, Tyk2 was chosen as the second signaling protein to be 
examined. A549 cells were infected with influenza A and Tyk2 and 
phosphorylated Tyk2 (P-Tyk2) were analyzed by Western blotting. As depicted in 
Fig. 26, P-Tyk2 was suppressed upon influenza A infection in IFN-α stimulated 
cells (lane4), compared to the Tyk2 phosphorylation in non-infected cells (lane3). 
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Tyk2 phosphorylation was not detected in non-stimulated protein extracts (lane 1 
& 2). The protein level of total Tyk2 protein remained equal for all cell lysates 
(lane 1-4). 
Influenza A was shown to inhibit the phosphorylation of Tyk2 and therefore also 
STAT1 phosphorylation. It remains to be seen whether direct binding of M1 to 
Tyk2 causes this inhibition, or whether RACK1 was recruited by M1, resulting in 
the destruction of the receptor complex and therefore impairing the Tyk2 
phosphorylation by Jak1. 
 
      1         2         3          4 
 
Figure 26: Inhibition of Tyk2 phosphorylation by influenza A 
infection of A549 cells. 12h p.i. cells were stimulated with IFN-α 
for 10min, harvested and proteins extracted. Lysates were 
subjected to Western blot analysis and examined for Tyk2 and 
P-Tyk2. 
 
8.6 INHIBITION OF STAT2 AND JAK1 
PHOSPHORYLATION BY INFLUENZA A 
As STAT2 is phosphorylated upon Tyk2 phosphorylation, it was assumed that the 
level of STAT2 phosphorylation (P-STAT2) might also be reduced. In order to 
determine the effect of influenza A on STAT2/P-STAT2, A549 cells were infected 
with influenza and proteins analyzed by Western blotting. In Fig. 27A, total 
STAT2 was detected equally in all cell lysates, STAT2 was thus not degraded by 
influenza. Analogous to P-STAT1, P-STAT2 was detected in non-
infected/stimulated (lane2) cells. This finding indicated the induction of the IFN-
α/β signaling cascade upon influenza infection. In influenza-infected cells, P-
STAT2 was inhibited upon IFN-α stimulation (lane4), compared to non-stimulated 
cells (lane3). 
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Furthermore, the phosphorylation status of Jak1 was assessed and the inhibition 
of its phosphorylation upon infection and stimulation identified. As shown in Fig. 
27B, phosphorylated Jak1 (P-Jak1) was detected in all cell lysates. P-Jak1 was 
shown in non-stimulated cells unlike the other IFN-α signaling proteins. This 
could either be explained by unspecific binding of the anti-P-Jak1 antibody to 
unphosphorylated Jak1 or by a basal phosphorylation status of Jak1 in non-
stimulated cells. However, in analogy to the other IFN-α signaling proteins, P-
Jak1 did not increase upon IFN-α stimulation in influenza-infected cells (lane 2 
and 4), indicating the interference with the IFN-α/β signaling pathway by an 
infecting virus. The protein level of Jak1 was equal for all cell lysates. 
Our data suggested that influenza A inhibited phosphorylation of STAT2 and 
Jak1. Further analysis will provide insight on mechanism of interference and on 
interaction partners of the virus in the type I IFN signaling pathway. 
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Figure 27: A: Inhibition of STAT2 phosphorylation upon influenza infection of A549 
cells. Cells were stimulated with IFN-α for 20min. B: Inhibition of Jak1 
phosphorylation upon influenza infection of A549 cells. Cells were stimulated with 
IFN-α for 10min. A&B: harvested 12h p.i. and proteins were extracted. Lysates 
were subjected to Western blot analysis and examined for STAT2, P-STAT2, Jak1 
and P-Jak1. 
 
8.7 PHOSPHORYLATION OF IFN-α/β SIGNALING 
PROTEINS UPON M1 TRANSFECTION 
In order to exclude the negative regulation of the IFN-α signaling proteins 
through other viral proteins, a transfection of pVR1012-M1 was performed in 
HEK293 cells. SV5 V-protein and RFP were used as positive and negative 
control, respectively. pVR1012 (empty vector: e.v.) served as another negative 
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control, which enabled to determine the effect of an overexpressed protein on the 
IFN-α/β signaling in the transfected cell. 
As shown in Fig. 28A, the phosphorylation of STAT1 was impaired upon 
transfection with M1 (lane1), compared to the cells transfected with RFP (lane3) 
or the empty vector (lane4). The transfection with SV5-V showed a significant 
decrease in the amount of P-STAT1. This finding was consistent with the data 
from literature, where SV5 V-protein was proposed to degrade STAT1, with the 
consequence of a decreased level of P-STAT1 (Didcock et al., 1999b). P-STAT2 
was decreased after M1-transfection compared to the empty vector, but equal to 
SV5 V and RFP. 
These findings confirmed the negative regulation of the IFN-α/β signaling 
pathway by M1. The inhibitory effect was confirmed to be dependent on the M1-
protein, as the phosphorylation and thus activation of the signaling proteins was 
decreased by transfection of pVR1012-M1. 
As depicted in Fig. 28B, the phosphorylation of Tyk2 was inhibited the amount of 
P-Tyk2 was higher in IFN-α stimulated cells transfected with 1/5xM1 than with 
1xM1. The negative regulation of M1 on the IFN-α signaling pathway was hereby 
shown to correlate with the amount of M1 in the cell. 
Furthermore non-stimulated, transfected HEK293 cells were observed for the 
phosphorylation of the IFN-α/β signaling proteins, as shown in Fig. 28C. These 
cells were not expected to display any phosphorylated IFN-α/β signaling proteins. 
However, P-STAT2 and P-STAT1 were detected 24h post transfection for all 
transfections. This finding indicated a toxic effect of the plasmids on the cells. 
The toxic effect led to the induction of endogenous IFN-α production and thus 
activation of the type I IFN signaling pathway. The amount of phosphorylated 
STAT’s was higher upon transfection with pVR1012, than upon transfection with 
pEFSV5-V or pDsRed1-C2. The plasmid pVR1012 was thus identified to be more 
toxic to the cells than pDsRed1-C2. pEFSV5-V and pVR1012-M1 showed a 
similar effect on the phosphorylation level of the lysates of IFN-α induced, 
transfected cells (Fig. 28A). The level of phosphorylation upon transfection with 
pEFSV5-V in the non-stimulated cells was higher than with pVR1012-M1 (Fig. 
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28C). The plasmid pEFSV5-V displayed also a toxic effect. Transfection with 
pVR1012-M1 revealed the lowest level of STAT-phosphorylation. This result 
confirmed the data of the IFN-α stimulated, transfected cells depicted in Fig. 28C. 
pVR1012 induced the IFN-α production by its backbone, but pVR1012 coding for 
the M1-protein inhibited the activation of the IFN-α/β signaling pathway, 
suggesting a specific inhibitory effect of viral M1-protein. 
 
 
8.8 JAK1, TYK2, STAT2 AND RACK1 AS INTERACTION 
PARTNERS OF M1 
The previous experiments gave evidence for a negative regulation of the IFN-α/β 
signaling pathway by the influenza A M1-protein. Interaction partners of M1 in 
this negative regulation were still unknown and had thus to be identified by a co-
immunoprecipitation experiment. Jak1, Tyk2, STAT2 and STAT1 were the first to 
be studied. They were shown to be inhibited in their phosphorylation and thus 
likely to be interaction partners of M1. 
A co-immunoprecipitation analysis was done in influenza-infected cells. Jak1, 
Tyk2, STAT1 or STAT2 were precipitated and M1 was detected in 
immunoprecipitates. The immunoprecipitation was shown in this direction only, 
B: 
 
A: 
       1         2       3        4 
 
C: 
 
Figure 28: Phosphorylation of IFN-α signaling proteins upon overexpression of M1 in 
HEK293 cells. Cells were harvested and proteins were analyzed by Western blotting detecting 
P-Jak1, P-Tyk2, P-STAT2 or P-STAT1. A: Cells were transfected with pVR1012M1, pEFSV5-
V, pDsRed1-C2 or pVR1012 and stimulated with IFN-α for 10 or 20min. B: HEK293 cells were 
transfected with 1/5 or 1 volume of pVR1012M1, or pVR1012 and stimulated with IFN-α for 
10min. C: Cells were transfected with pVR1012M1, pEFSV5-V, pDsRed1-C2 or pVR1012. 
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as for the precipitation of the M1-protein with detection of the IFN-α/β signaling 
proteins no bands were detected. 
Lysates were precipitated with an unspecific antibody in order to detect 
unspecific binding of M1 to the Protein-A agarose beads. As depicted in Fig. 29, 
M1 was detected after infection in immunoprecipitation analysis with Jak1, Tyk2, 
STAT2 and RACK1. Precipitation of Tyk2 displayed a strong band with the 
specific antibody only. The precipitation with Jak1 and STAT2 showed a stronger 
band with the specific antibody (anti-Jak1 or anti-STAT2, respectively; lane3), 
than the band with the unspecific antibody (anti-myosin; lane4). Therefore the 
interaction between Jak1-M1 and STAT2-M1 was determined to be specific. 
Immunoprecipitation with STAT1 did not reveal any band, indicating that there 
was no binding between STAT1-M1. Furthermore a co-immunoprecipitation 
experiment between RACK1 and M1 was performed. M1 and RACK1 were 
shown to be interaction partners in a yeast-two-hybrid assay (Reinhardt & Wolff, 
2000). The precipitation of M1 along with RACK1 would be expected. The 
RACK1 precipitation was done with lysates of infected HEK293 cells, as depicted 
in Fig. 29. Specific interaction of M1 with RACK1 was identified (lane3). The 
interaction resulted in a band with the specific antibody (anti-RACK1) only, which 
led to the conclusion that the beads for RACK1 (protein-L agarose beads) did not 
interact unspecifically with M1 as did the protein-A agarose beads, used for the 
other IFN-α signaling proteins. 
Thus, M1 was suggested to interact with Jak1, Tyk2, STAT2 and RACK1. The 
phosphorylation of Jak1, Tyk2 and STAT2 was inhibited and the binding of 
STAT1 to the receptor complex and thus the phosphorylation of STAT1 blocked. 
Therefore, the activation of the IFN-α/β signaling cascade was impaired by M1. 
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A: 
    1       2       3      4 
 
Figure 29: Co-immunoprecipitation revealed Jak1, Tyk2 and 
RACK1 as interaction partners of the M1-protein. Cells were 
harvested and proteins were extracted 12h p.i.. Western blot 
analysis was performed detecting M1. A co-
immunoprecipitation was performed with HEK293 cells using 
specific antibodies (sAB) to precipitate Jak1, Tyk2, STAT1, 
STAT2 and RACK1 and anti-myosin as unspecific antibody 
to determine unspecific binding of M1 to the beads. 
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9 DISCUSSION 
The type I IFN system is a highly evolved system that protects humans and 
animals from viral infection and plays an important role in the establishment of 
the antiviral state upon infection of a cell. Signaling induced by IFN-α/β and 
derived from the IFN receptor through the JAK-STAT pathway, mediates rapid 
and robust transcriptional induction of genes encoding antiviral proteins. The 
interplay between IFN and virus might affect viral pathogenicity, clearance and 
host immunity. Viruses encoding IFN antagonists often display increased 
virulence. Using various strategies, DNA and RNA viruses can inhibit IFN 
induced host defense mechanisms. Some viruses reduce the basal levels of 
particular molecules of the Jak-STAT pathway and others inactivate components 
of the Jak-STAT pathway. 
It was previously reported that the influenza A NS1 protein repressed the antiviral 
response by multiple mechanisms. These mechanisms included the inhibition of 
the IFN inducible enzymes PKR and OAS (Bergmann et al., 2000, Tan & Katze, 
1998) and the blocking of IFN-β production by preventing NF-κB, IRF3, and IRF7 
activation (Smith et al., 2001, Talon et al., 2000, Wang et al., 2000). The 
generation of a recombinant influenza A/PR/8/34 virus lacking the NS1 gene 
(delNS1) impaired its ability to replicate in MDCK cells, reducing the viral growth 
by three logs compared to the wild type virus. As the delNS1 influenza virus 
deletion mutant was only partially attenuated (Garcia-Sastre et al., 1998b), it was 
assumed that additional influenza virus genes contributed to the virus mediated 
block of the antiviral-response (Geiss et al., 2002).  
The scaffold protein RACK1 was shown in literature to act as a scaffold for the 
IFN receptor complex (Yokota et al., 2003) and for the phosphorylation of the 
influenza A M1-protein (Reinhardt & Wolff, 2000). These findings suggested the 
M1-protein as a potent antagonist of the IFN-α signaling pathway. We 
hypothesized that RACK1 may be the target protein for a negative regulation of 
the IFN-α/β signaling by the M1-protein. In the present study, we show the 
negative regulation of the innate immune response; more precisely the IFN-α 
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induced antiviral response following influenza A infection in various cell lines. 
Influenza A was found to have acquired the ability, to target the JAK-STAT 
signaling cascade for evading the IFN response. The IFN-α signaling pathway 
was examined by infection with influenza and transfection of the M1 protein. The 
data presented here demonstrate that the M1-protein of influenza is an 
antagonist of the IFN-α signaling pathway. 
 
The influenza virus infection and the overexpression of M1 reduced the IFN-α/β 
stimulated transcription of the FFL reporter gene upon addition of excess 
amounts of IFN-α. The FFL activity was inhibited by 80% in HEK293 cells and by 
50% in Vero cells. The difference in the suppression between the two cell lines 
may be explained by the infection efficiency, which was higher for the HEK293 
cells. Non-stimulated, infected HEK293 cells showed a weak, but significant 
increase in FFL activity, compared to non-infected cells (Fig. 20A). Such a 
response is considered to be an indirect effect involving an intermediary IFN 
release. Influenza A has been shown to induce the expression of the antiviral 
protein Mx (Lee et al., 2000). This mechanism of induction is known to be 
mediated by interaction of dsRNA with TLR3 and leads to the production of type I 
IFNs (Alexopoulou et al., 2001, Matsumoto et al., 2004). This induction in FFL 
activity was not observed in Vero cells, as they do not possess the genes for type 
I IFNs. 
The FFL reporter assay demonstrated a reduction in ISRE-promoter activity in 
IFN-α induced M1 transfected cells, when compared with induced RFP 
transfected cells. The M1-protein displayed antagonistic activity similar to the 
SV5 V-protein, which is known to be a strong inhibitor of the IFN-α signaling 
pathway (Didcock et al., 1999a, Didcock et al., 1999b). The M1-protein is the 
most abundant protein in the influenza A virus. A virus particle includes about 
3000 molecules of the M1-protein and the amount increases rapidly upon 
infection. It is assumed that the IFN-α/β signaling pathway was suppressed very 
efficiently, considering the excess amount of M1 in the infected cell. The strength 
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of M1 as an IFN-α/β antagonist may be a combination of the abundance of the 
protein and its potency as an inhibitor. 
The result of the reporter gene assay was independently confirmed by the 
detection of lower protein levels of MxA in IFN-α stimulated, influenza infected 
cells. MxA is a key effector in the IFN-α/β signaling pathway and known to be 
specifically induced by type I IFNs in mammals (for review see Haller and Kochs, 
2002). 
For efficient replication, most viruses have evolved the ability to code for IFN 
antagonistic molecules, capable of blocking one or more steps in the IFN system. 
The JAK-STAT pathway is a frequent point of interference by viruses, as it 
induces the activation of many antiviral genes (Sen, 2001). Some 
paramyxoviruses, such as SV5 and parainfluenza virus type 2 (HPIV2) have 
been shown to block IFN signal transduction by targeting the STAT1 and STAT2 
proteins respectively for degradation (Didcock et al., 1999a, Didcock et al., 
1999b, Parisien et al., 2001). Rabies virus has been shown to inhibit the 
translocation of activated STAT1 in the nucleus (Brzozka et al., 2006). Measles 
virus was shown to inhibit the antiviral activity by suppression of Jak1 
phosphorylation, and Sendai virus (SeV) and Japanese encephalitis virus (JEV) 
were shown to interfere with the JAK-STAT signaling through the blocking of 
Tyk2 phosphorylation (Komatsu et al., 2000, Lin et al., 2004). Since 
approximately 400 genes are known to be transcriptionally stimulated by type I 
IFNs (Der et al., 1998), it is perhaps not surprising that for most viruses, the exact 
mechanism involved in blocking these complex signal transduction pathways 
remain to be fully elucidated. Indeed, despite intensive studies, the detailed 
mechanism of action responsible for the IFN antagonistic properties of the 
influenza NS1 protein remains to be elucidated (Garcia-Sastre, 2004). 
The phosphorylation analysis of the IFN-α/β signaling proteins in influenza-
infected cells gave evidence for the interference of the M1-protein with the JAK-
STAT pathway. Phosphorylation of Jak1, Tyk2, STAT1 and STAT2 were 
suppressed upon IFN-α stimulation in influenza-infected cells and Tyk2, STAT1 
and STAT2 in M1 transfected cells. Jak1 and Tyk2, bound to IFN receptor 
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complex, initiate the IFN-α/β signaling cascade. The suppression of the IFN-α/β 
signaling cascade was proposed to inhibit the phosphorylation of STAT1 and 
STAT2 as a consequence of inhibited phosphorylation of Jak1 and Tyk2. This 
finding is similar to the mechanism of IFN-α/β signaling suppression found in tick-
borne encephalitis (TBE) viruses. TBE blocks the IFN-α signaling by inhibition of 
Jak1 and Tyk2 phosphorylation (Best et al., 2005), which suppresses the 
downstream signaling of IFN-α/β. The transcript level of total Jak1, Tyk2, STAT1 
and STAT2 remained constant, showing that influenza infection did not induce 
proteolysis in this time frame. 
The actual interference of the M1-protein with the IFN-α/β signaling pathway was 
examined by a co-immunoprecipitation experiment, where Jak1, Tyk2, STAT2 
and RACK1 were identified to be interaction partners of M1 in influenza infected 
cells. The experimental procedure did not allow to determine whether the 
interaction between the five proteins was direct or indirect. Future studies are 
required to determine the details of the protein interaction. Moreover, the 
observation did not allow us to determine whether the IFN-α stimulation of 
infected cells led to a single type of interaction complex: M1 with Jak1, Tyk2, 
STAT2 and RACK1 and eventually other, currently unknown proteins, or whether 
the interaction between the signaling kinases Jak1, Tyk2, STAT2 and M1, and 
between the scaffold RACK1 and M1 were independent interactions. If the 
interactions with the M1-protein were independent from each other, they may 
also function independently in infected cells. One function would be the negative 
regulation of the IFN-α/β signaling and the other function would be the 
phosphorylation of the M1-protein by PKC (Reinhardt & Wolff, 2000). 
 
Taken together, the complex interplay between M1 and the IFN-α/β signaling 
proteins could be narrowed down to two possible models (illustrated in Fig. 30): 
(A) Upon influenza infection the scaffold protein RACK1 associated to the IFN 
receptor complex is recruited by M1. The receptor complex would thereby be 
destroyed and the signaling cascade of IFN-α/β blocked. The suppression of the 
IFN-α/β signaling, caused by the defective receptor complex would be a 
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secondary effect of the need of M1 phosphorylation. Jak1 and Tyk2 were 
identified as interaction partners of M1 because the interaction with RACK1 was 
maintained. (B) Upon influenza infection, M1 binds to Jak1, Tyk2 and RACK1 on 
the IFN-α receptor complex. The membrane-associated complex is not 
destroyed. The interaction can lead to the inhibition of the IFN-α/β signaling only, 
and the phosphorylation of M1 would be an independent reaction, or the 
phosphorylation of M1 occurs at the IFN-α/β receptor complex, thereby masking 
the phosphorylation sites of Jak1 and Tyk2. 
 
 
 
Figure 30: Model for the interaction of the influenza A M1-protein with the IFN-α/β 
signaling proteins. Two different models could explain the negative regulation of the IFN-
α/β signaling pathway by M1: (A) The scaffold protein RACK1 is recruited by M1 for its 
phosphorylation by PKC. This leads to the destruction of the IFN receptor complex and 
thus the block of the IFN-α/β signaling pathway. As M1 was precipitated with the kinases 
Jak1 and Tyk2, they were expected to bind the M1-phosphorylation complex. (B) M1 
binds to the IFN receptor complex directly or indirectly binding Jak1, Tyk2 and RACK1 
and blocks thereby phosphorylation of Jak1, Tyk2 and STAT2, and binding of STAT1. In 
vivo, the situation could be either of the two models or a combination of them. 
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In addition to the inhibitory effect of the M1-protein on the IFN-α/β signaling 
pathway, an independent effect was observed by the detection of MxA in infected 
A549 cells. Analysis of MxA by Western blotting showed a significant decrease in 
MxA protein content (Fig. 22B), if A549 cells were infected with influenza A and 
proteins were extracted 20h to 24h later. This phenomenon was observed 
without IFN-α stimulation. The effect was thus not a consequence of the time gap 
between influenza infection and IFN-α stimulation of the cells. MxA remains 
stable in the cells for several days after synthesis (Aebi et al., 1989). Therefore, 
our observation led to the conclusion that MxA was actively degraded by 
influenza A. The influenza A polymerase A subunit (PA) was shown to induce 
proteolysis upon infection of a cell (Hara et al., 2001, Sanz-Ezquerro et al., 
1995). PA may be responsible for the degradation of MxA. Further experiments 
remain to be done in order to proof this hypothesis. This proteolytic activity would 
represent the third protein of influenza A, displaying antagonistic activity against 
the innate immune response. This indicates the importance of the suppression of 
the IFN system for the virulence of the influenza A virus, as it was previously 
described for other viruses. 
 
This study elucidated the M1-protein as second influenza protein, interfering with 
the innate immune response. Until now, the influenza virus displays two proteins 
counteracting the innate immune response, the NS1 protein by suppression of 
the IFN-α/β production, and the M1-protein by inhibition of the expression of IFN 
inducible genes. This additional strategy against the innate immune system 
enables the virus to replicate in cells stimulated by paracrine or endocrine 
secreted IFN-α. The virus displays an enhanced virulence and is therefore well 
prepared to counteract the host cell defense. The identification of an IFN 
antagonist protein in influenza A represents an important step in understanding 
influenza virus-host interactions since inhibition of the IFN system is known to 
play an important role in pathogenicity, immunogenicity, persistence and 
tissue/host tropism (Didcock et al., 1999a, Garcia-Sastre et al., 1998a). 
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Experimental data have shown the importance of adaptive immune response, 
especially the antibody response upon influenza virus infection (Graham et al., 
1994). The importance of a potent antibody response for viral clearance might be 
a consequence of the efficient suppression of IFN-α/β induction/signaling by 
influenza virus. 
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10 OUTLOOK 
This study showed an alternative mechanism of influenza to counteract the 
innate immune system. We identified the influenza protein M1 as interaction 
partner of several IFN-α signaling proteins. 
An interesting approach for the future would be to find out whether M1-protein de 
novo synthesis is required for the negative regulation of the innate immune 
response in influenza infected cells. Therefore cells could be infected with 
inactivated, but morphologically intact virus (inactivation by UV light, which 
destroys the RNA, but not the proteins). As the viral protein synthesis would be 
blocked, a possible effect upon infection would originate in the antagonistic 
activity of M1 protein brought into the cell by the virus particle. It remains to be 
examined whether the amount of M1-protein brought into the cell by infection is 
sufficient for IFN-α signaling suppression. 
 
This study identified influenza A to contain a proteolytic activity, responsible for 
the degradation of MxA. It was speculated that the polymerase subunit PA of 
influenza A encodes a proteolytic activity (Perales et al., 2000, Sanz-Ezquerro et 
al., 1995). Our finding together with this hypothesis would present an interesting 
investigation for a future project. 
 
It is known from literature that M1 is phosphorylated by PKC, and that M1 has 
different functions depending on its phosphorylation status. It would be 
interesting to know whether the phosphorylation status of M1 is related to its 
activity in IFN-α signaling cascade. 
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